U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒

QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, ~~201~~20920

☐

TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT

For the Transition Period from to

Commission file number 1-13463

BIO-KEY INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in Its Charter)

DELAWARE	41-1741861
(State or Other Jurisdiction of Incorporation of Organization)	(IRS Employer Identification Number)

3349 HIGHWAY 138, BUILDING A, SUITE E, WALL, NJ 07719

(Address of Principal Executive Offices)

(732) 359-1100

(Registrant’s telephone number, including area code)

Securities registered pursuance to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered

Common Stock, par value $0.0001 per share	BKYI	Nasdaq ~~Stock market~~Capital Market

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller Reporting Company ☒

~~Non-accelerated filer ☐~~

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined by rule 12b-2 of the Exchange Act) Yes ☐ No ☒

Number of shares of Common Stock, $.0001 par value per share, outstanding as of August 12, ~~2019~~2020 is ~~14,397,015.~~ 60,434,315.

Table of Contents

BIO-KEY INTERNATIONAL, INC. AND ~~SUBSIDIARY~~SUBSIDIARIES

INDEX

PART I. FINANCIAL INFORMATION

Item 1	—	Condensed Consolidated Financial Statements (unaudited):
		Balance sheets as of June 30, ~~2019~~2020 (unaudited) and December 31, ~~2018~~2019 (audited)	3
		Statements of operations for the three and six months ended June 30, ~~2019~~2020 and ~~2018~~2019	4
			Statements of Stockholders’ Equity (Deficit) for the three and six months ended June 30, ~~2019~~2020 and ~~2018~~2019	5
		Statements of cash flows for the six months ended June 30, ~~2019~~2020 and ~~2018~~2019	7
		Notes to condensed consolidated financial statements	9

~~Item 2~~	—	~~Management’s Discussion and Analysis of Financial Conditions and Results of Operations.~~	22

~~Item 4~~	—	~~Controls and Procedures.~~	29

~~PART II. OTHER INFORMATION~~

Item 2	—	~~Unregistered Sales~~Management’s Discussion and Analysis of ~~Equity Securities~~Financial Conditions and ~~Use~~Results of ~~Proceeds.~~Operations.	30

~~Item 6~~	—	~~Exhibits.~~	3025

~~Signatures~~Item 4	31—	Controls and Procedures.	33

PART II. OTHER INFORMATION

Item 1A	—	Risk Factors	34

Item 2	—	Unregistered Sales of Equity Securities and Use of Proceeds.	35

Item 6	—	Exhibits.	36

Signatures			37

Table of Contents

PART I -- FINANCIAL INFORMATION

BIO-KEY INTERNATIONAL, INC. AND ~~SUBSIDIARY~~SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2019			December 31, 2018			June 30, 2020			December 31, 2019
	(Unaudited)						(Unaudited)
ASSETS
Cash and cash equivalents	$	687,023		$	323,943		$	886,664		$	79,013
Accounts receivable, net		689,900			1,574,032			315,341			126,000
Due from factor		138,568			56,682			79,634			110,941
Inventory		1,011,703			998,829			388,898			429,119
Prepaid expenses and other								98,641			108,397
Investment								516,121			512,821
Total current assets								2,285,299			1,366,291
Resalable software license rights		1,125,000			1,125,000			68,774			73,802
Prepaid expenses and other		161,997			150,811
Total current assets		3,814,191			4,229,297
Resalable software license rights, net of current portion		6,193,417			6,790,610
Equipment and leasehold improvements, net		137,458			148,608			95,545			95,509
Capitalized contract costs, net		278,286			319,199			176,345			231,519
Deposits and other assets		8,712			8,712			8,712			8,712
Operating lease right-of-use assets		532,757			-			552,954			566,479
Intangible assets, net		191,014			195,906			2,147,197			154,386
Goodwill								417,171			-
Total non-current assets		7,341,644			7,463,035			3,466,698			1,130,407
TOTAL ASSETS	$	11,155,835		$	11,692,332		$	5,751,997		$	2,496,698

LIABILITIES
Accounts payable	$	864,879		$	481,269		$	668,474		$	844,557
Accounts payable – related party		142,623			-			66,466			188,737
Accrued liabilities		714,250			548,232			380,462			572,885
Convertible notes payable, net of debt discount and debt issuance costs		541,667			-			2,201,017			2,255,454
Note payable - PistolStar								500,000			-
Deferred revenue		294,261			196,609			602,779			359,212
Operating lease liabilities, current portion		141,068			-			204,282			170,560
Total current liabilities		2,698,748			1,226,110			4,623,480			4,391,405
Operating lease liabilities, net of current portion		383,028			-			346,064			390,466
Total non-current liabilities		383,028			-			346,064			390,466
TOTAL LIABILITIES		3,081,776			1,226,110			4,969,544			4,781,871

Commitments

STOCKHOLDERS’ EQUITY
STOCKHOLDERS’ EQUITY (DEFICIT)

Common stock — authorized, 170,000,000 shares; issued and outstanding; 14,295,923 and 13,977,868 of $.0001 par value at June 30, 2019 and December 31, 2018, respectively		1,429			1,398
Common stock — authorized, 170,000,000 shares; issued and outstanding; 22,181,315 and 14,411,432 of $.0001 par value at June 30, 2020 and December 31, 2019, respectively								2,218			1,441
Additional paid-in capital		86,436,197			85,599,140			95,558,928			87,436,402
Accumulated deficit		(78,363,567	)		(75,134,316	)		(94,778,693	)		(89,723,016	)
TOTAL STOCKHOLDERS’ EQUITY		8,074,059			10,466,222
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	11,155,835		$	11,692,332
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)								782,453			(2,285,173	)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)							$	5,751,997		$	2,496,698

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

BIO-KEY INTERNATIONAL, INC. AND ~~SUBSIDIARY~~SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three months ended
June 30,

Six months ended
June 30,

2019

2018

2019

2018

Revenues

Services
$ 231,993 $ 249,121 $ 473,603 $ 551,570
License fees
60,300 154,251 143,508 256,970
Hardware
436,090 344,769 662,895 781,056
Total revenues
728,383 748,141 1,280,006 1,589,596
Costs and other expenses

Cost of services
58,421 120,841 149,250 275,573
Cost of license fees
372,327 766,637 749,543 1,540,102
Cost of hardware
248,678 142,325 384,683 393,573
Total costs and other expenses
679,426 1,029,803 1,283,476 2,209,248
Gross profit (loss)
48,957 (281,662
)
(3,470
)
(619,652
)

Operating Expenses

Selling, general and administrative
1,058,671 1,076,184 2,435,704 2,538,038
Research, development and engineering
301,217 297,633 675,335 689,787
Total Operating Expenses
1,359,888 1,373,817 3,111,039 3,227,825
Operating loss
(1,310,931
)
(1,655,479
)
(3,114,509
)
(3,847,477
)
Other income (expense)

Interest income
54 14 124 21
Interest expense
(114,866
)
- (114,866
)
-
Total other income (expense), net
(114,812
)
14 (114,742
)
21
Net loss
(1,425,743
)
(1,655,465
)
(3,229,251
)
(3,847,456
)
Convertible preferred stock dividends
- (41,870
)
- (198,033
)
Net loss available to common stockholders
$ (1,425,743
)
$ (1,697,335
)
$ (3,229,251
)
$ (4,045,489
)

Basic and diluted loss per common share attributable to common stockholders
$ (0.10
)
$ (0.15
)
$ (0.23
)
$ (0.42
)

Weighted Average Common Shares Outstanding:

Basic and diluted
14,117,062 11,375,320 14,048,570 9,623,151

~~The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.~~

~~BIO-key International, Inc. and Subsidiaries~~

~~CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY~~

~~(Unaudited)~~

	Three months ended June 30,						Six months ended June 30,
	2020			2019			2020			2019
Revenues
Services	$	229,503		$	231,993		$	437,026		$	473,603
License fees		23,542			60,300			258,887			143,508
Hardware		54,097			436,090			133,714			662,895
Total revenues		307,142			728,383			829,627			1,280,006
Costs and other expenses
Cost of services		92,672			58,421			163,117			149,250
Cost of license fees		8,255			372,327			18,711			749,543
Cost of hardware		47,527			248,678			90,889			384,683
Total costs and other expenses		148,454			679,426			272,717			1,283,476
Gross profit (loss)		158,688			48,957			556,910			(3,470	)

Operating Expenses
Selling, general and administrative		1,211,928			1,058,671			2,593,327			2,435,704
Research, development and engineering		318,573			301,217			655,462			675,335
Total Operating Expenses		1,530,501			1,359,888			3,248,789			3,111,039
Operating loss		(1,371,813	)		(1,310,931	)		(2,691,879	)		(3,114,509	)
Other income (expense)
Interest income		25,801			54			25,802			124
Government grant – Paycheck Protection Program		340,819			-			340,819			-
Interest expense		(567,516	)		(114,866	)		(2,118,657	)		(114,866	)
Loss on extinguishment of debt		-			-			(499,076	)		-
Total other income (expense), net		(200,896	)		(114,812	)		(2,251,112	)		(114,742	)
Net loss		(1,572,709	)		(1,425,743	)		(4,942,991	)		(3,229,251	)
Deemed dividends related to down-round features		-			-			(112,686	)		-
Net loss available to common stockholders	$	(1,572,709	)	$	(1,425,743	)	$	(5,055,677	)	$	(3,229,251	)

Basic and diluted loss per common share	$	(0.08	)	$	(0.10	)	$	(0.28	)	$	(0.23	)

Weighted Average Common Shares Outstanding:
Basic and diluted		20,864,866			14,117,062			18,030,939			14,048,570

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

~~BIO-key~~BIO-key International, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

Series A-1
Preferred Stock

Series B-1
Preferred Stock

Common Stock

Additional
Paid-in

Accumulated

Shares

Amount

Shares

Amount

Shares

Amount

Capital

Deficit

Total

Balance as of December 31, 2017
62,596 $ 6 105,000 $ 11 7,691,324 $ 769 $ 80,829,001 $ (67,076,492
)
$ 13,753,295
Adoption of ASC 606
- - - - - - - 240,017 240,017
Issuance of common stock for directors’ fees
- - - - 8,421 1 16,512 - 16,513
Dividends declared on preferred stock
- - - - - - (156,162
)
- (156,162
)
Conversion of B-1 preferred stock to common stock
- - (60,420
)
(6
)
1,678,334 168 (162
)
- -
Conversion of dividends payable on B-1 preferred stock
- - - - 115,857 11 417,072 - 417,083
Share-based compensation
- - - - - - 533,421 - 533,421
Net loss
- - - - - - - (2,191,992
)
(2,191,992
)
Balance as of March 31, 2018
62,596 $ 6 44,580 $ 5 9,493,936 $ 949 $ 81,639,682 $ (69,028,467
)
$ 12,612,175
Issuance of common stock for directors’ fees
- - - - 2,683 1 6,508 - 6,509
Dividends declared on preferred stock
- - - - - - (41,871
)
- (41,871
)
Conversion of A-1 preferred stock to common stock
(62,596
)
(6
)
- - 1,738,778 174 (168
)
- -
Conversion of dividends payable on A-1 preferred stock
- - - - 98,893 10 356,005 - 356,015
Conversion of B-1 preferred stock to common stock
- - (44,580
)
(5
)
1,238,334 123 (118
)
- -
Conversion of dividends payable on B-1 preferred stock
- - - - 15,373 2 55,339 - 55,341
Legal fees
- - - - - - (15,212
)
- (15,212
)
Share-based compensation
- - - - - - 143,034 - 143,034
Net loss
- - - - - - - (1,655,465
)
(1,655,465
)
Rounding - - - - - - - 1 1
Balance as of June 30, 2018
- $ - - $ - 12,587,997 $ 1,259 $ 82,143,199 $ (70,683,931
)
$ 11,460,527

~~The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.~~

~~BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY~~

~~CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS~~

~~(Unaudited)~~

Six Months Ended June 30,

2019

2018

CASH FLOW FROM OPERATING ACTIVITIES:

Net loss
$ (3,229,251
)
$ (3,847,456
)
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:

Depreciation
39,903 44,596
Amortization of intangible assets
6,628 8,966
Amortization of resalable software license rights
562,150 1,318,559
Amortization of debt discount
15,467 -
Amortization of capitalized contract costs
67,774 59,044
Amortization of debt issuance costs 56,200 -
Share and warrant-based compensation for employees and consultants
635,077 676,454
Stock based directors’ fees
22,011 23,021
Change in assets and liabilities:

Accounts receivable
884,132 2,424,295
Due from factor
(81,886
)
82,202
Operating leases right-of-use assets 70,180 -
Capitalized contract costs
(26,861
)
(160,649
)
Inventory
(12,874
)
16,369
Resalable software license rights
35,043 9,543
Prepaid expenses and other
(23,781 ) (4,041
)
Accounts payable
526,233 (168,799
)
Accrued liabilities
166,018 (203,445
)
Deferred revenue
97,652 (179,683
)
Operating lease liabilities
(66,246
)
-
Net cash provided by (used for) operating activities
(256,431
)
98,976
CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of intangible assets
(1,736
)
-
Capital expenditures
(28,753
)
(68,479
)
Net cash used for investing activities
(30,489
)
(68,479
)
CASH FLOW FROM FINANCING ACTIVITIES:

Issuance of convertible notes
667,000 -
Costs to issue notes, preferred and common stock
(17,000 ) (15,212
)
Net cash provided by (used for) financing activities
650,000 (15,212
)
NET INCREASE IN CASH AND CASH EQUIVALENTS
363,080 15,285
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
323,943 288,721
CASH AND CASH EQUIVALENTS, END OF PERIOD
$ 687,023 $ 304,006

	Common Stock					Additional Paid-in			Accumulated
	Shares		Amount			Capital			Deficit			Total
Balance as of January 1, 2020		14,411,432	$	1,441		$	87,436,402		$	(89,723,016	)	$	(2,285,173	)
Issuance of common stock pursuant to securities purchase agreements		700,000		70			1,032,430			-			1,032,500
Commitment fee adjustment		-		-			(900,000	)		-			(900,000	)
Beneficial conversion feature		-		-			641,215			-			641,215
Issuance of common stock pursuant to warrant exercises		972,000		97			1,457,903			-			1,458,000
Issuance of common stock for conversion of convertible note payable		2,307,690		231			1,499,769			-			1,500,000
Deemed dividends related to down-round features		-		-			112,686			(112,686	)		-
Share-based compensation		-		-			512,719			-			512,719
Net loss		-		-			-			(3,370,282	)		(3,370,282	)
Balance as of March 31, 2020		18,391,122	$	1,839		$	91,793,124		$	(93,205,984	)	$	(1,411,021	)
Issuance of common stock for directors’ fees		17,140		2			15,005			-			15,007
Issuance of common stock pursuant to securities purchase agreements		251,518		25			145,308			-			145,333
Warrants issued with convertible notes		-		-			1,388,339			-			1,388,339
Warrant issued for consulting fees		-		-			94,655			-			94,655
Legal and commitment fees		-		-			(199,328	)		-			(199,328	)
Issuance of common stock for conversion of convertible note payable		3,521,535		352	��		2,288,648			-			2,289,000
Share-based compensation		-		-			33,177			-			33,177
Net loss		-		-			-			(1,572,709	)		(1,572,709	)
Balance as of June 30, 2020		22,181,315	$	2,218		$	95,558,928		$	(94,778,693	)	$	782,453

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

~~BIO-KEY I~~~~nternational,~~BIO-key International, Inc. and ~~Subsidiary~~Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

	Common Stock				Additional Paid-in			Accumulated
	Shares		Amount		Capital			Deficit			Total
Balance as of January 1, 2019		13,977,868	$	1,398	$	85,599,140		$	(75,134,316	)	$	10,466,222
Issuance of common stock for directors’ fees		13,820		1		16,505			-			16,506
Share-based compensation		-		-		509,528			-			509,528
Net loss		-		-		-			(1,803,508	)		(1,803,508	)
Balance as of March 31, 2019		13,991,688	$	1,399	$	86,125,173		$	(76,937,824	)	$	9,188,748
Issuance of common stock for directors’ fees		4,235		-		5,505			-			5,505
Issuance of common stock pursuant to securities purchase agreements		300,000		30		449,970			-			450,000
Commitment fee adjustment		-		-		(270,000	)		-			(270,000	)
Share-based compensation		-		-		125,549			-			125,549
Net loss		-		-		-			(1,425,743	)		(1,425,743	)
Balance as of June 30, 2019		14,295,923	$	1,429	$	86,436,197			(78,363,567	)	$	8,074,059

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
~~(Unaudited)~~

~~SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION~~(Unaudited)

Six Months Ended June 30,

2019

2018

Cash paid for:

Interest
$ — $ —
Income taxes
$ — $ —

Noncash investing and financing activities

Accrual of unpaid dividends on preferred stock
$ — $ 198,033
Conversion of A-1 preferred dividends payable to common stock
$ — $ 356,015
Conversion of A-1 preferred stock to common stock
$ — $ 6,259,600
Conversion of B-1 preferred dividends payable to common stock
$ — $ 472,426
Conversion of B-1 preferred stock to common stock
$ — $ 10,500,000
Right-of-use asset addition under ASC 842
$ 602,937 $ —
Operating lease liabilities under ASC 842
$ 590,342 $ —
Share based commitment fees $ 180,000 $ —
Debt discount issued with convertible note $ 40,000 $ —

	Six Months Ended June 30,
	2020			2019

CASH FLOW FROM OPERATING ACTIVITIES:
Net loss	$	(4,942,991	)	$	(3,229,251	)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation		39,919			39,903
Amortization of intangible assets		12,189			6,628
Amortization of software license rights		-			562,150
Amortization of capitalized contract costs		73,660			67,774
Amortization of debt discount		398,929			15,467
Amortization of debt issuance costs		981,529			56,200
Operating leases right-of-use assets		92,632			70,180
Loss on extinguishment of debt		499,076			-
Amortization of beneficial conversion feature		641,215			-
Interest expense capitalized to note payable		96,984			-
Share and warrant-based compensation for employees and consultants		640,551			635,077
Stock based directors’ fees		15,007			22,011
Change in assets and liabilities:
Accounts receivable		(4,549	)		884,132
Due from factor		31,307			(81,886	)
Capitalized contract costs		(18,486	)		(26,861	)
Inventory		40,221			(12,874	)
Resalable software license rights		5,028			35,043
Prepaid expenses and other		19,241			(23,781	)
Accounts payable		(298,797	)		526,233
Accrued liabilities		(192,917	)		166,018
Deferred revenue		(9,601	)		97,652
Operating lease liabilities		(89,787	)		(66,246	)
Net cash used for operating activities		(1,969,640	)		(256,431	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of PistolStar		(2,000,000	)		(1,736	)
Cash acquired from purchase of PistolStar		100,747			-
Proceeds from maturity of investment		512,821			-
Purchase of investment		(516,121	)		-
Capital expenditures		(3,489	)		(28,753	)
Net cash used for investing activities		(1,906,042	)		(30,489	)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes		3,958,000			667,000
Costs to issue convertible notes		(398,412	)		(17,000	)
Proceeds from warrant exercises		1,458,000			-
Repayment of convertible note		(211,984	)		-
Net repayments of related party loans		(122,271	)		-
Net cash provided by financing activities		4,683,333			650,000
NET INCREASE IN CASH AND CASH EQUIVALENTS		807,651			363,080
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		79,013			323,943
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	886,664		$	687,023

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

BIO-KEY International, Inc. and Subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION

	Six Months Ended June 30,
	2020		2019

Cash paid for:
Interest	$	—	$	—
Income taxes	$	—	$	—

Noncash investing and financing activities
Accounts receivable acquired from PistolStar	$	184,792	$	—
Prepaid expenses acquired from PistolStar	$	9,485	$	—
Equipment acquired from PistolStar	$	36,467	$	—
Intangible assets acquired from PistolStar	$	2,005,000	$	—
Goodwill related to PistolStar acquisition	$	417,171	$	—
Issuance of note payable for PistolStar acquisition	$	500,000		—
Accrued expenses acquired from PistolStar	$	494	$	—
Deferred revenue acquired from PistolStar	$	253,168	$	—
Right-of-use asset addition under ASC 842	$	79,107	$	602,937
Operating lease liability addition under ASC 842	$	79,107	$	590,342
Issuance of common stock pursuant to securities purchase agreements	$	277,833	$	180,000
Warrants issued with convertible notes	$	1,388,339	$	-
Debt discount issued with convertible note	$	551,250	$	40,000
Deemed dividends related to down-round features	$	112,686	$	—
Issuance of common stock for conversion of note payable	$	3,789,000	$	—
Beneficial conversion feature	$	641,215	$	—
Legal and commitment fees related to debt and equity included in accounts payable	$	122,714	$	—

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

BIO-KEY INTERNATIONAL, INC. AND ~~SUBSIDIARY~~SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, ~~201~~20920 (Unaudited)

1.	NATURE OF BUSINESS AND BASIS OF PRESENTATION

Nature of Business

The Company, founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as ~~personal inspection identification,~~ passwords, tokens, keys, smart ~~cards, ID~~ cards, PKI, credit card, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned ~~subsidiary~~subsidiaries (collectively, the “Company” or “BIO-key”) and are stated in conformity with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules and regulations, certain financial information and ~~note~~footnote disclosures normally included in the financial statements have been condensed or omitted. Significant intercompany accounts and transactions have been eliminated in consolidation.

In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at ~~June 30,~~December 31, 2019 was derived from the audited financial statements, but does not include all of the disclosures required by accounting principles generally accepted in the United States of America. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, ~~2018,~~2019, filed with the SEC on ~~April 1, 2019.~~

May 14, 2020, and the 8-K/A disclosing the financial statements of PistolStar, Inc. (“PistolStar”) filed on July 28, 2020.

~~Updated Significant Accounting Policies~~New Significant Accounting Policies

~~Leases~~Business Combinations

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, “Leases” (Topic 842), as amended (ASC 842). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classify as either operating or finance leases. We adopted this standard effective January 1, 2019 using the modified retrospective approach for all leases entered into before the effective date. Adoption of the ASC 842 had a significant effect on our balance sheet resulting in increased non-current assets and increased current and non-current liabilities. There was no impact to retained earnings upon adoption of the new standard. We did not have any finance leases (formerly referred to as capital leases prior to the adoption of ASC 842), therefore there was no change in accounting treatment required. For comparability purposes, the Company will continue to comply with the previous disclosure requirements in accordance with the existing lease guidance and prior periods are not restated.

The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases.

In accordance with ASC ~~842,~~805, Business Combinations (ASC 805), the Company recognizes the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Determining these fair values requires management to make significant estimates and assumptions, especially with respect to intangible assets.

The Company recognizes identifiable assets acquired and liabilities assumed at their acquisition date fair value. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair value of the assets acquired and the liabilities assumed and represents the expected future economic benefits arising from other assets acquired that are not individually identified and separately recognized. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the ~~inception~~acquisition date, its estimates are inherently uncertain and subject to refinement. Assumptions may be incomplete or inaccurate, and unanticipated events or circumstances may occur, which may affect the accuracy or validity of ~~an arrangement,~~such assumptions, estimates or actual results. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill to the extent that it identifies adjustments to the preliminary purchase price allocation. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.

Goodwill and acquired intangible assets

Goodwill is not amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit, based on the Company’s market capitalization, and compares this amount to the carrying value of the reporting unit. If the Company determines ~~whether~~that the ~~arrangement is or contains~~carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The annual goodwill impairment test will be performed as of December 31^st of each year. To date, the Company has not identified any impairment to goodwill.

Intangible assets acquired in a ~~lease~~business combination are recorded at their estimated fair values at the date of acquisition. The Company amortizes acquired definite-lived intangible assets over their estimated useful lives based on the ~~unique facts and circumstances present and the classification~~pattern of consumption of the ~~lease including whether the contract involves the use~~economic benefits or, if that pattern cannot be readily determined, on a straight-line basis.

Table of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as right-of-use (ROU) assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component.

Contents

Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.

An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.

For periods prior to the adoption of ASC 842, the Company recorded rent expense based on the term of the related lease. The expense recognition for operating leases under ASC 842 is substantially consistent with prior guidance. As a result, there are no significant differences in our results of operations presented.

~~The impact of the adoption of ASC 842 on the balance sheet was:~~

As reported

Adoption of ASC

Balance

December 31,
2018

842 - increase
(decrease)

January 1,
2019

Operating lease right-of-assets
$ - $ 602,937 $ 602,937
Prepaid expenses and other
$ 150,811 $ (12,595
)
$ 138,216
Total assets
$ 11,692,332 $ 590,342 $ 12,282,674
Operating lease liabilities, current portion
$ - $ 135,519 $ 135,519
Operating lease liabilities, net of current portion
$ - $ 454,823 $ 454,823
Total liabilities
$ 1,226,110 $ 590,342 $ 1,816,452
Total liabilities and stockholders’ equity
$ 11,692,332 $ 590,342 $ 12,282,674

Recently Issued Accounting Pronouncements

In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update to the standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. Entities can choose to adopt ~~the~~ ASU 2018-15 prospectively or retrospectively. The Company ~~is currently assessing the impact~~has assessed that ASU 2018-15 ~~will~~currently does not have a material impact on its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. ASU 2016-13 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, ~~2019.~~2022 for smaller reporting companies. Early adoption is permitted. The Company is currently assessing the impact ASU 2016-13 will have on its condensed consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

Reclassification

Reclassifications occurred to certain prior year amounts in order to conform to the current year ~~classifications including segregating the hardware revenues.~~classifications. The reclassifications have no effect on the reported net loss.

2.	GOING CONCERN

The Company has incurred significant losses to date, and at June 30, ~~2019~~2020 had an accumulated deficit of approximately ~~$78~~$95 million. In addition, broad commercial acceptance of the Company’s technology is critical to the Company’s success and ability to generate future revenues. At June 30, ~~2019,~~2020, the Company’s total cash and cash equivalents were approximately ~~$687,000,~~$887,000, as compared to approximately ~~$324,000~~$79,000 at December 31, ~~2018.~~2019.

The Company has financed operations in the past through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. ~~The~~With its new acquisition, the Company estimates that it currently requires approximately ~~$537,000~~$680,000 per month to conduct operations, a monthly amount that it has been unable to achieve consistently through revenue generation.

IfIn July of 2020, the Company ~~is unable~~raised approximately $22.8 million, after deducting the underwriting discounts and commissions and estimated offering expenses. The Company used approximately $4.2 million of the net proceeds of the Offering to ~~generate sufficient revenue~~satisfy all outstanding amounts due under convertible promissory notes previously issued to ~~meet its goals, it will need~~Lind Global Macro Fund, L.P. and there are no longer any remaining amounts due. We anticipate using these funds to ~~obtain additional third-party financing to (i) conduct the sales, marketing and technical support necessary~~help fulfill two contracts in Africa. Our ability to execute and deliver on these contracts in Africa, our ability to expand into Asia, Africa and other foreign markets, the duration and severity of the current coronavirus COVID-19 pandemic and its ~~plan~~effect on our business operations, sales cycles, personnel, and the geographic markets in which we operate, delays in the development of products and statements of assumption underlying any of the foregoing will affect our ability to substantially grow operations, increase revenue, and serve a significant customer base; and (ii) provide working capital. No assurance can be given that any form of additional financing will be available on terms acceptable to the Company, that adequate financing will be obtained by the Company, in order to meet its needs, or that such financing would not be dilutive to existing shareholders.achieve profitability.

~~The accompanying~~Due to several factors, including our history of losses and limited revenue, our independent auditors have included an explanatory paragraph in their opinion related to our annual financial statements ~~have been prepared in conformity with accounting principles generally accepted in~~as to the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The matters described in the preceding paragraphs raise substantial doubt about ~~the Company’s~~our ability to continue as a going concern. ~~Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent~~Our long-term viability and growth will depend upon the ~~Company’s~~successful commercialization of our technologies and expansion of operations, and to pursue merger or acquisition candidates. As we move forward, we will reevaluate our going concern, based on our ability to ~~meet its financing requirements on~~generate a continuing basis, and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.profit.

Table of Contents

3.	REVENUE FROM CONTRACTS WITH CUSTOMERS

~~The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption.~~ In accordance with ASC 606, revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps:

	●	Identify the contract with a customer
	●	Identify the performance obligations in the contract
	●	Determine the transaction price
	●	Allocate the transaction price to performance obligations in the contract
	●	Recognize revenue when or as the Company satisfies a performance obligation

Disaggregation of Revenue

The following table summarizes revenue from contracts with customers for the three month periods ended June 30, ~~2019~~2020 and June 30, ~~2018:~~2019:

	North America		South America		EMEA*		Asia		June 30, 2019		North America		South America		EMEA*		Asia		June 30, 2020

Support and Maintenance	$	197,613	$	5,291	$	22,589	$	3,500	$	228,993
Professional services		3,000		-		-		-		3,000
Services											$	209,846	$	375	$	10,934	$	8,348	$	229,503
License fees		32,800		-		27,500		-		60,300		23,542		-		-		-		23,542
Hardware		124,416		12,236		294,627		4,811		436,090		48,327		-		-		5,770		54,097
Total Revenues	$	357,829	$	17,527	$	344,716	$	8,311	$	728,383	$	281,715	$	375	$	10,934	$	14,118	$	307,142

	North America		South America		EMEA*		Asia		June 30, 2018		North America		South America		EMEA*		Asia		June 30, 2019

Support and Maintenance	$	225,602	$	16	$	12,503	$	3,000	$	241,121
Professional services		6,000		-		2,000		-		8,000
Services											$	200,613	$	5,291	$	22,589	$	3,500	$	231,993
License fees		69,151		30,000		55,100		-		154,251		32,800		-		27,500		-		60,300
Hardware		120,496		53,040		10,298		160,935		344,769		124,416		12,236		294,627		4,811		436,090
Total Revenues	$	421,249	$	83,056	$	79,901	$	163,935	$	748,141	$	357,829	$	17,527	$	344,716	$	8,311	$	728,383

The following table summarizes revenue from contracts with customers for the six month periods ended June 30, ~~2019~~2020 and June 30, ~~2018:~~

2019:

	North America		South America		EMEA*		Asia		June 30, 2019		North America		South America		EMEA*		Asia		June 30, 2020

Support and Maintenance	$	392,938	$	7,407	$	59,007	$	8,501	$	467,853
Professional services		3,750		-		-		2,000		5,750
Services											$	406,162	$	750	$	14,701	$	15,413	$	437,026
License fees		47,008		-		27,500		69,000		143,508		188,777		-		-		70,110		258,887
Hardware		170,398		12,636		327,545		152,316		662,895		104,681		-		-		29,033		133,714
Total Revenues	$	614,094	$	20,043	$	414,052	$	231,817	$	1,280,006	$	699,620	$	750	$	14,701	$	114,556	$	829,627

	North America		South America		EMEA*		Asia		June 30, 2018		North America		South America		EMEA*		Asia		June 30, 2019

Support and Maintenance	$	403,518	$	16	$	21,216	$	16,970	$	441,720
Professional services		107,850		-		2,000		-		109,850
Services											$	396,688	$	7,407	$	59,007	$	10,501	$	473,603
License fees		130,120		30,000		96,850		-		256,970		47,008		-		27,500		69,000		143,508
Hardware		220,086		53,040		225,074		282,856		781,056		170,398		12,636		327,545		152,316		662,895
Total Revenues	$	861,574	$	83,056	$	345,140	$	299,826	$	1,589,596	$	614,094	$	20,043	$	414,052	$	231,817	$	1,280,006

*EMEA – Europe, Middle East, Africa

Table of Contents

All of the ~~Company's~~Company’s performance obligations, and associated revenue, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.

Software licenses

Software license revenue consist of fees for perpetual and software as a service (SaaS) software licenses for one or more of the Company’s biometric fingerprint solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.

Hardware

Hardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are not obligated to buy third party hardware from the Company, and may procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.

Support and Maintenance

Support and Maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its Support and Maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of invoice until the contracts term occurs. Revenue is recognized over time on a ratable basis over the contract term. Support and Maintenance contracts are up to one year in length and are generally invoiced either annually or quarterly in advance. Support and Maintenance revenue for SaaS license is carved out of the total license cost at 18% and recognized on a ratable basis over the license term.

Professional Services

Professional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC 606-10-55-18. For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.

Contracts with Multiple Performance Obligations

Some contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.

The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software. These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.

Accounts receivable from customers are typically due within 30 days of invoicing. The Company does not record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.

Costs to Obtain and Fulfill a Contract

Costs to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be four years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations.

~~Revenue recognized during the three and six months ended June 30, 2019 from amounts included in deferred revenue at the beginning~~

Table of the period was approximately $34,000 and $111,000 respectively. The Company did not recognize any revenue from performance obligations satisfied in prior periods. Total deferred revenue (contract liability) was $294,261 and $196,609 at June 30, 2019 and December 31, 2018, respectively.
Contents

Transaction Price Allocated to the Remaining Performance Obligations

ASC 606 requires that the Company disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as at June 30, ~~2019.~~2020. The guidance provides certain practical expedients that limit this requirement, which the Company’s contracts meet as follows:

●

The performance obligation is part of a contract that has an original expected duration of one year or less, in accordance with ASC 606-10-50-14.

At June 30, ~~2019~~2020 deferred revenue represents our remaining performance obligations related to support and maintenance, all of which is expected to be recognized within one year.

Revenue recognized during the three and six months ended June 30, 2020 from amounts included in deferred revenue at the beginning of the period was approximately $36,000 and $108,000 respectively. The Company did not recognize any revenue from performance obligations satisfied in prior periods. Total deferred revenue (contract liability) was $602,779 and $359,212 at June 30, 2020 and December 31, 2019, respectively.

4.	PistolStar, Inc. acquisition

On June 30, 2020, the Company entered into a stock purchase agreement pursuant to which it acquired PistolStar, Inc., a private company based in the United States, that provides enterprise-ready identity access management solutions, including multi-factor authentication, identity-as-a-service, single sign-on and self-service password reset to commercial, government and education customers throughout the United States and internationally.

From April 10, 2020 until we acquired PistolStar, we licensed PortalGuard®, PistolStar’s authentication software, which the Company combines with its biometric authentication solutions offered to existing and prospective customers.

The total purchase price of $2.5 million included cash payments of $2.0 million and the issuance of a $500,000 promissory note.

The acquisition of PistolStar has been accounted for as a business combination and, in accordance with ASC 805,the Company has recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following table summarizes the preliminary purchase price allocation as of June 30, 2020:

Purchase consideration:

Total cash paid, net of acquired cash
$ 2,000,000
4% Promissory note
500,000
Total purchase price consideration
$ 2,500,000

Fair value of assets acquired and liabilities assumed:

Cash and cash equivalents
$ 100,747
Accounts receivable
184,792
Prepaid expenses and other current assets
9,485
Fixed assets
36,467
Intangible assets
2,005,000
Goodwill
417,171
Total assets acquired
2,753,662

Accrued expenses and other current liabilities
494
Deferred revenue
253,168
Total fair value of assets acquired and liabilities assumed
$ 2,500,000

The promissory note, which was issued to the previous owner of PistolStar, carries interest at 4% per annum and is payable in four installments over the 12-month period following the closing.

Table of Contents

In the three months ended June 30, 2020, acquisition-related expenses were immaterial. Acquisition-related expenses have been included primarily in general and administrative expenses in the condensed consolidated statements of operations. The operating results of PistolStar will be included in the condensed consolidated statements of operations beginning on July 1, 2020.

The significant intangible assets identified in the purchase price allocation discussed above include customer relationships, which are amortized over their respective useful lives on a straight-line basis when the pattern in which their economic benefits will be consumed cannot be reliably determined. To value the developed technology asset, the Company utilized the income approach, specifically a discounted cash-flow method known as the multi-period excess earnings method. Customer relationships represent the underlying relationships with certain customers to provide ongoing services for products sold. The Company utilized the income approach, specifically the distributor method, a subset of the excess-earnings method to value the customer relationships.

The fair value of the assets acquired and liabilities assumed reflected in the tables above is less than the purchase price, resulting in the recognition of goodwill. The goodwill reflects the value of the synergies the Company expects to realize and the assembled workforce.

The following table presents the preliminary fair values and useful lives of the identifiable intangible assets acquired:

Amount

Estimated useful life
(in years)

Developed technology
$ 1,153,000 3
Customer relationships
852,000 5
Total identifiable intangible assets
$ 2,005,000

Pro Forma Financial Information (unaudited)

The following unaudited pro forma information presents the combined results of operations of the Company and PistolStar for the three and six month periods ended June 30, 2020 as if the acquisition of PistolStar had been completed on January 1, 2020. These pro forma financial results have been prepared for comparative purposes only and include certain adjustments that reflect pro forma results of operations such as fair value adjustments (step-downs) for deferred revenue, increased amortization for the fair value of acquired intangible assets and adjustments to eliminate transaction costs incurred by the Company and PistolStar.

The unaudited pro forma results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of the operations of the Company and PistolStar. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of the results of operations that would have been achieved had the acquisition occurred as of January 1, 2020, nor are they intended to represent or be indicative of future results of operations (in thousands, except per share amounts):

3 Months ended June 30,

6 Months ended June 30,

2020

2020

Revenue
$ 725,779 $ 1,652,678
Net loss
(1,580,349
)
(5,045,889
)
Basic and diluted net loss per share
$ (0.08
)
$ (0.28
)
Weighted average number of ordinary shares used in computing basic and diluted loss per share
20,864,866 18,030,939

5.	ACCOUNTS RECEIVABLE

Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible.

As a result of the payment delays ~~for~~from a large customer, the Company has reserved $1,720,000 at June 30, ~~2019~~2020 and December 31, ~~2018,~~2019, which represents 100% of the remaining balance owed under the ~~contract, respectively.~~contract. Recoveries of accounts receivable previously written off are recorded when received. Additionally, the Company sold a license to a Chinese reseller in December 2018. Revenue was recognized in accordance with ASC 606 in the amount of $1.1 million in 2018. As of December 31, 2019, the second payment due to be paid in March 2019 for $555,555 was still outstanding and payable. As of December 31, 2019, the Company wrote off the amount directly to bad debt expense as it was determined not to be collectible.

Table of Contents

Accounts receivable at June 30, ~~2019~~2020 and December 31, ~~2018~~2019 consisted of the following:

	June 30,			December 31,			June 30,			December 31,
	2019			2018			2020			2019

Accounts receivable - current	$	703,685		$	1,587,817		$	329,126		$	139,785
Accounts receivable - non current		1,720,000			1,720,000			1,720,000			1,720,000
Total accounts receivable		2,423,685			3,307,817			2,049,126			1,859,785

Allowance for doubtful accounts - current		(13,785	)		(13,785	)		(13,785	)		(13,785	)
Allowance for doubtful accounts - non current		(1,720,000	)		(1,720,000	)		(1,720,000	)		(1,720,000	)
Total allowance for doubtful accounts		(1,733,785	)		(1,733,785	)		(1,733,785	)		(1,733,785	)

Accounts receivable, net of allowance for doubtful accounts	$	689,900		$	1,574,032		$	315,341		$	126,000

5.6.	SHARE BASED COMPENSATION

The following table presents share-based compensation expenses included in the Company’s unaudited condensed interim consolidated statements of operations:

	Three Months Ended June 30,				Three Months Ended June 30,
	2019		2018		2020		2019

Selling, general and administrative	$	115,526	$	128,620	$	140,328	$	115,526
Research, development and engineering		15,528		20,922		2,511		15,528
	$	131,054	$	149,542	$	142,839	$	131,054

	Six Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2020		2019

Selling, general and administrative	$	568,613	$	599,766	$	581,636	$	568,613
Research, development and engineering		88,475		99,709		73,922		88,475
	$	657,088	$	699,475	$	655,558	$	657,088

6.7.

FACTORING

Due from factor consisted of the following as of:

	June 30,			December 31,			June 30,			December 31,
	2019			2018			2020			2019

Original invoice value	$	555,075		$	221,120		$	189,037		$	233,005
Factored amount		(416,507	)		(164,438	)		(109,403	)		(122,064	)
Due from factor	$	138,568		$	56,682		$	79,634		$	110,941

Table of Contents

The Company entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) ~~which has been extended to~~expiring on October 31, ~~2019.~~2020. Pursuant to the terms of the arrangement, the Company, from time to time, sells to the Factor a minimum of $150,000 per quarter of certain of its accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to the Company (the “Advance Amount”), with the remaining balance, less fees, ~~to be~~ forwarded to the Company once the Factor collects the full accounts receivable balance from the customer. In addition, the Company, from time to time, receives over advances from the ~~factor.~~Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored, and are determined by the number of days required for collection of the invoice. The cost of factoring is included in selling, general and administrative expenses. The cost of factoring was as follows:

Three Months ended
June 30,

2019

2018

Factoring fees
$ 39,543 $ 12,691

Three Months ended
June 30,

2020

2019

Factoring fees
$ 33,230 $ 39,543

Six Months ended
June 30,

2019

2018

Factoring fees
$ 92,340 $ 104,214

Six Months ended
June 30,

2020

2019

Factoring fees
$ 65,230 $ 92,340

7.8.

INVENTORY

Inventory is stated at the lower of cost, determined on a first in, first out basis, or net realizable value, and consists primarily of fabricated assemblies and finished goods. Inventory is comprised of the following as of:

	June 30,		December 31,		June 30,		December 31,
	2019		2018		2020		2019

Finished goods	$	499,426	$	496,358	$	247,540	$	287,761
Fabricated assemblies		512,277		502,471		141,358		141,358
Total inventory	$	1,011,703	$	998,829	$	388,898	$	429,119

8.9.	RESALABLE SOFTWARE LICENSE RIGHTS

On November 11, 2015, the Company entered into a license agreement for the rights to all software and documentation regarding the technology currently known as or offered under the FingerQ name. The license agreement grants the Company the exclusive right to reproduce, create derivative works and distribute copies of the FingerQ software and documentation, create new FingerQ related products, and grant sub-licenses of the licensed technology to end users. The license rights have been granted to the Company in perpetuity, with a stated number of end-user resale sub-licenses allowed under the contract for a total of $12,000,000. ~~The cost of sub-license rights expected to be amortized in the following 12 months is $1,125,000 and is classified as current, with remainder as non-current.~~

The Company ~~originally~~initially determined the software license rights to be a finite lived intangible asset, and estimated that the software license rights shall be economically used over a ~~10 year~~10-year period, with a weighting towards the beginning years of that time-frame. The license rights were acquired during the fourth quarter of 2015, but the usage of such rights in the Company’s products was not generally available until January 2017. Accordingly, amortization began in the first quarter of 2017.

Through December 31, 2018, the ~~remaining~~ license rights were amortized over the greater of the following amounts: 1) an estimate of the economic use of such license rights, 2) the amount calculated by the straight line method over ten years or 3) the actual cost basis of sales usage of such rights. ~~The Company believes that the economic use model was front-end focused as a majority~~After re-evaluation of the expected ~~up-take~~timeline of ~~the FingerQ technology was predicted to occur during the first 4-5 years of the 10-year life cycle of the product. Based on current sales trends,~~future license transactions, commencing January 1, 2019, the Company ~~now believes future transactions will be more evenly dispersed over the remaining life cycle of the product, indicating that~~changed its amortization methodology to the greater of the straight-line methodology or actual unit cost per license sold ~~will more closely align the expense with the remaining useful life of the product. The change in amortization was effective beginning on January 1, 2019~~ based on ~~the~~ net remaining software ~~license rights balance.~~licenses as of January 1, 2019. The Company ~~believes categorizing~~categorized the amortization expense under Cost of Sales as it more closely ~~reflects~~reflected the nature of the license right arrangement and the use of the technology.

During the fourth quarter of 2019, the Company re-evaluated the recoverability of the carrying amount of the balance of license rights, and concluded that there were no significant undiscounted cash flows expected to be generated from the future sale of the license rights. Accordingly, an impairment charge of $6,957,516 was recorded in the fourth quarter of 2019, which reduced the carrying amount of the FingerQ license rights down to zero. Throughout 2019, the Company attempted to sell the technology into the mobile market in Asia, but due to, among other things, the trade tension between the US and China, management concluded that the future amortization would not represent an accurate cost to the ongoing business, without corresponding revenue. A total of ~~$281,250~~$281,076 and ~~$660,000~~$174 was charged to cost of sales during the ~~three month periods~~three-month period ended June 30, 2019 for amortization and ~~2018, respectively, and of this amount $174 and $855, represent~~ the cost basis of the actual sales, respectively. A total of ~~$562,500~~$562,150 and ~~$1,320,000~~$350 was ~~expensed~~charged to cost of sales during the ~~six month periods~~six-month period ended June 30, 2019 for amortization and ~~2018, respectively and of this amount $350 and $1,441 represent~~ the cost basis of the actual sales, respectively. ~~Since the license purchase, a cumulative amount of $4,761,096 has been charged to cost of sales, with a carrying balance of $7,238,904 as of June 30, 2019.~~

The Company's change in methodology was determined to be a change in accounting estimate that is effected by a change in accounting principle. Pursuant to ASC 250-10-45-17 guidance, this accounting change will not be accounted for as a cumulative effect adjustment on the statement of operations in the period of change and there will be no retroactive application or restatement of prior periods. Instead, the Company allocates the remaining unamortized balance over the remaining life of the assets using the newly adopted method.

~~The following compares line items on the statement of operations had the change in amortization methodology not been made:~~

As reported

Prior methodology

As reported

Prior methodology

3 months ended

3 months ended

6 months ended

6 months ended

June 30, 2019

June 30, 2019

June 30, 2019

June 30, 2019

Amortization of software license rights
$ 281,076 $ 749,826 $ 562,150 $ 1,499,650
Total operating expenses
$ 1,359,888 $ 1,828,638 $ 3,111,039 $ 4,048,539
Operating loss
$ (1,310,931
)
$ (1,779,681
)
$ (3,114,509
)
$ (4,052,009
)
Net loss
$ (1,425,743
)
$ (1,894,493
)
$ (3,229,251
)
$ (4,166,751
)
Basic & diluted loss per share
$ (0.10
)
$ (0.13
)
$ (0.23
)
$ (0.29
)

On December 31, 2015, the Company purchased third-party software licenses in the amount of $180,000 in anticipation of a large pending deployment that has yet to materialize. The Company is amortizing the total cost over the same methodology described above with the greatest of the two approaches being the actual unit cost per license sold. A total of $0 and $8,739 ~~and $20,642~~ was ~~expensed~~charged to cost of sales during the three month periods ended June 30, ~~2019~~2020 and ~~2018,~~2019, respectively. A total of $5,028 and $34,693 ~~and $8,102 (net~~was charged to cost of ~~credits of $14,400) was expensed~~sales during the six month periods ended June 30, ~~2019~~2020 and ~~2018,~~2019, respectively. Since the license purchase, the actual per unit cost (actual usage) of such license rights in the cumulative amount of ~~$100,487~~$111,226 has been charged to cost of sales, with a carrying balance of ~~$79,513~~$68,774 and $73,802 as of June 30, ~~2019. The Company has classified the balance as non-current until a larger deployment occurs. Software license rights is comprised of the following as of:~~

2020 and December 31, 2019, respectively.

June 30,

December 31,

2019

2018

Current resalable software license rights
$ 1,125,000 $ 1,125,000
Non-current resalable software license rights
6,193,417 6,790,610
Total resalable software license rights
$ 7,318,417 $ 7,915,610
16
Table of Contents

9.10.

~~Related Party~~INVESTMENT

During ~~the six months ended June 30,~~ 2019, the Company purchased a 4,000,000 Hong Kong dollar denominated Bond Certificate with a financial institution in Hong Kong. The Bond Certificate translated to $512,821 U.S. Dollars on June 2019 purchase date. The bond had a one-year term which matured in June 2020, bearing interest at 5% per annum. The Company redeemed the bond and recorded interest income of approximately $25,800. The Company then purchased a new 4,000,000 Hong Kong dollar denominated Bond Certificate with a financial institution in Hong Kong in June 2020. The new Bond Certificate translated to $516,121 U.S. Dollars, based on the exchange rate at purchase date. The Company can invest up to 20,000,000 Hong Kong dollars under the terms of the certificate, bearing interest at 5% per annum. The bond is classified on the balance sheet as an investment. The investment is recorded at amortized cost which approximates fair value, and is currently planned to be held to maturity.

11.	Related Party TRANSACTIONS

The Company has received a series of non-interest-bearing advances from ~~an executive officer/~~Mr. Wong Kwok Fong, a director of the ~~Company's principal stockholder,~~Company, and Mr. Michael DePasquale, the Company’s Chief Executive Officer, to pay current liabilities. The balance of the ~~advance~~advances as at June 30, 2020 was $66,466 and $0, respectively, and as of December 31, 2019 was ~~$142,623,~~$74,737 and $114,000, respectively. The balance owed is ~~payable upon~~due on demand.

Sales Incentive Agreement with TTI

On March 25, 2020, the Company entered into a sales incentive agreement Technology Transfer Institute (“TTI”). One of the Company’s board members is the Chief Executive Officer of TTI. Terms of the agreement include the following:

The term of the agreement is one year unless notice to terminate (as defined) is given. The agreement will be automatically extended for additional one-year terms unless terminated.

For each $5,000,000 in revenue (up to a maximum of $20,000,000) TTI generates during the first year that generates net income of at least 20% (as defined), the Company will pay TTI a sales incentive fee of $500,000 payable by the issuance of 500,000 shares of common stock.

In the event that TTI generates revenue in excess of $20,000,000 during the first year, the Company will issue TTI a five-year warrant to purchase 100,000 shares of Common Stock at an exercise price of $1.50 per share for each $1,000,000 of revenue in excess of $20,000,000 (up to a maximum of $25,000,000).

In no event will the Company be obligated to issue more than 2,000,000 shares of common stock or warrants to purchase more than 500,000 shares of common stock pursuant to this agreement.

There has been no revenue generated nor sales incentive fees paid during the three and six months ended June 30, 2020.

~~10.~~12.

Convertible NOTES PAYABLE

Convertible notes payable as of June 30, 2020 and December 31, 2019 consist of the following:

June 30,

December 31,

2020

2019

Securities Purchase Agreement dated July 10, 2019
$ - $ 2,255,454
January 2020 Note
- -
February 2020 Note
150,849 -
May 2020 Note
1,196,837 -
June 2020 Note
853,331 -
Convertible notes payable, net
$ 2,201,017 $ 2,255,454

Table of Contents

Securities Purchase Agreement dated July 10, 2019

On ~~April 4,~~July 10, 2019, the Company issued a ~~$550,000~~$3,060,000 principal amount senior secured convertible ~~debenture which matures November 15, 2019~~note (the “Original Note”). At closing, a total of $2,550,000 was funded. The original issue discount was $510,000. The principal amount due of the Original Note was due and ispayable as follows: $918,000 was due 180 days after funding, $1,071,000 was due 270 days after funding, and the remaining balance due 12 months after the date of funding.

The Original Note was secured by a lien on substantially all of the Company’s assets and properties and was convertible ~~into~~at the option of the Investor in shares of common stock at a fixed conversion price of $1.50 per share. The ~~note may be redeemed~~Company had the right to prepay the Original Note in full at any time ~~by payment~~without penalty in which event, the Investor had the option of converting 25% of the outstanding principal amount of the Note into shares of common stock.

In connection with the closing of the Original Note, the Company issued a ~~premium~~five-year warrant to the ~~principal balance starting at 5% and increasing~~Investor to ~~25%. The note was issued at approximately 7% ($40,000) original issue discount. Subject to the mutual agreement of the Company and the investor, the Company may~~ purchase two additional $550,000 principal amount note on the same terms after 45 day intervals from the prior issuance, for an additional potential net proceeds of $1,020,000. The convertible note contains anti-dilution protections if the Company issues2,000,000 shares of common stock ~~for less than the conversion price. The convertible note was secured substantially by all the assets~~at a fixed exercise price of ~~the Company. At the closing, the Company~~$1.50 per share, paid a $50,000 commitment fee, and issued ~~80,000~~266,667 shares of common stock in payment of a ~~$120,000 commitment fee~~$400,000 due diligence fee. The Company also paid banker fees of $193,500 and ~~is obligated to issue 10,000 shares~~legal fees of ~~common stock monthly in payment of a monthly commitment fee of $15,000 until the earlier of November 1, 2019 or the repayment or conversion~~$71,330. The valuation of the ~~note.~~

~~On June 14, 2019, the Company issued a $157,000 secured 10% convertible redeemable note which matures November 14, 2019 and is convertible into common stock at a conversion price~~warrant of $1.50 per share. The convertible redeemable note contains anti-dilution protections if the Company offers a conversion discount or other more favorable conversion terms while the note is in effect. The note may be redeemed within the first five months by payment of a premium to the principal balance starting at 10% and increasing to 30% of principal plus interest. At the closing, the Company issued 200,000 shares of common stock in lieu of payment of a $30,000 commitment fee. If the note is repaid prior to the maturity date, 180,000 of the shares shall be returned to the Company.

~~Both notes were repaid on July 10, 2019.~~

~~For the two notes issued during the second quarter of 2019, the Company issued a total of 300,000 shares of common stock, amounting to $450,000 in commitment fees. Of these amounts, $180,000~~$595,662 was recorded ~~as an offset~~ to ~~notes payable –~~ debt ~~issuance costs~~discount and iswas amortized over the life of the ~~loan.~~Original Note. The ~~return of commitment fee in amount of $270,000 (180,000 shares) was recorded as a reduction in additional paid in capital and shares~~fees associated with the agreement were ~~returned~~allocated to ~~the Company on July 10, 2019. The Company also incurred $17,000 of legal fees withheld from proceeds which was also recorded as an offset to notes payable –~~ debt issuance costs and ~~amortized over~~additional paid-in capital based on the ~~life~~respective ratio of the ~~loan.~~valuation of the note and warrant. Amortization of the debt issuance costs and debt discount are included in interest expense on the statement of operations.

~~Convertible notes~~On March 12, 2020, the Company issued a $3,789,000 principal amount senior secured convertible note (the “Amended Note”), which replaced the Original Note. The principal amount was due and payable in full on April 13, 2020. The Amended Note was secured by a lien on substantially all of the Company’s assets and properties and was convertible at the option of the Investor into shares of common stock at a fixed conversion price of $0.65 per share. Due to the debt restructuring, the balance of the Amended Note was increased by an additional $729,000 in interest. The Company accounted for the transaction as a debt extinguishment, and therefore, the balance of the fees and unamortized discount associated with the Original Note were written off and included as loss on extinguishment of debt. On the day of the conversion, the closing stock price for the day was $0.76, which resulted in a beneficial conversion of $0.11 per share outstanding or $641,215 to be amortized to interest expense over the term of the Amended Note as adjusted for any debt conversion.

On April 12, 2020, and May 6, 2020, the Company entered into amendments (the “Amendments”) to the Amended Note. The Amendments extended the maturity date to June 12, 2020 and extended the Investor’s right to convert the Amended Note into shares of the Company’s common stock at a price of $0.65 per share through June 12, 2020. All other provisions of the Amended Note remained the same.

Until the second anniversary of the closing, the Investor has the right to purchase up to 20% of the securities the Company issues in any future private placement, subject to certain exceptions for, among other things, strategic investments.

On June 10, 2020, the Investor converted the last of the remaining principal into shares of common stock for payment in full, and as of June 30, 2020, the remaining principal balance is $0. The Amended Note amount of $3,789,000 was converted into 5,829,225 shares of common stock.

June 30,

December 31,

2020

2019

Principal amount
$ 3,789,000 $ 3,060,000
Less: conversion of principal into shares of common stock
(3,789,000
)
-
Net Principal amount
- 3,060,000

Less: unamortized debt discount and beneficial conversion feature
- (574,330
)
Less: unamortized debt issuance costs
- (230,216
)
Notes payable, net of unamortized debt discount and debt issuance costs
$ - $ 2,255,454

January 2020 Note

On January 13, 2020, the Company issued a $157,000 principal amount secured 10% convertible redeemable note (the “January 2020 Note”) to an institutional investor with a maturity date of June 13, 2020 which was convertible into common stock at a conversion price of $1.50 per share. The January 2020 Note was redeemable at any time by payment of a premium to the principal balance starting at 10% and increasing to 30%. At the closing, the Company agreed to issue 650,000 shares of common stock in lieu of payment of a $75,000 commitment fee which would be reduced to 50,000 shares if the January 2020 Note is repaid prior to the maturity date. The Company paid $7,000 of legal fees for the January 2020 Note.

On June 12, 2020, the January 2020 Note was paid in full for $211,984. The 600,000 shares were returned to the Company in July 2020.

Table of Contents

February 2020 Note

On February 13, 2020, the Company issued a $126,000 principal amount secured 10% convertible redeemable note (the “February 2020 Note”) to an institutional investor with a maturity date of July 13, 2020 which was convertible into common stock at a conversion price of $1.15 per share. On March 12, 2020, the Original Note was amended to reduce the conversion price to $0.65 per share, which reduced the conversion price of the February Note to $0.65 and resulted in an additional deemed dividend expense of $70,998. The February 2020 Note was redeemable at any time by payment of a premium to the principal balance starting at 10% and increasing to 30%. The Company issue 50,000 shares of common stock to the investor in lieu of payment of a $57,500 commitment fee. The Company paid $6,000 of legal fees in connection with the issuance of February 2020 Note.

This February 2020 Note was paid in full on July 10, 2020 by payment of $170,442.

The February 2020 Note, net of unamortized debt issuance costs consisted of:

June 30,

December 31,

2020

2019

Principal amount
$ 126,000 $ -
Add: prepayment premium
37,170 -
Add: accrued interest
4,830 -
Less: unamortized debt issuance costs
(17,151 ) -
Notes payable, net of unamortized debt issuance costs
$ 150,849 $ -

May 2020 Note

On May 6, 2020, the Company issued a $2,415,000 principal amount senior secured convertible note (the “May 2020 Note”). At closing, $2,100,000 was funded. The principal amount is due and payable in five equal monthly installments of $268,333 beginning seven months after the funding date with the remaining balance due on the twelfth month after the date of funding. The Note is convertible at a fixed convertible price of $1.16 per share. In connection with the issuance of the May 2020 Note, the Company paid a $133,333 due diligence fee by issuing 114,943 shares to the Investor priced at $1.16 per share. The Company also paid a placement fee of 7% of the gross proceeds to a placement agent. In connection with the closing of the May 2020 Note, the Company issued a five-year warrant to the investor to purchase 1,900,000 shares of common stock at a fixed exercise price of $1.16 and was immediately exercisable. The valuation of the warrant of $876,937 was recorded to debt discount and is being amortized over the life of the May 2020 Note. The fees associated with the agreement were allocated to debt issuance costs ~~at June 30, 2019 consist~~and additional paid-in-capital based on the respective ratio of the valuation of the note and warrant. Amortization of the debt issuance costs and debt discount are included in the interest expense on the statement of operations.

Following the completion of the underwritten offering consummated in July 2020, all outstanding amounts due under the May 2020 Note were paid in full.

The May 2020 Note, net of unamortized debt issuance costs consisted of:

Principal amount
$ 707,000
Less unamortized debt discount
(24,533 )
Less unamortized debt issuance costs
(140,800 )
Notes payable, net of unamortized debt discount and debt issuance costs
$ 541,667

June 30,

December 31,

2020

2019

Principal amount
$ 2,415,000 $ -
Less: unamortized debt discount
(1,013,146
)
-
Less: unamortized debt issuance costs
(205,017
)
-
Notes payable, net of debt discount and unamortized debt issuance costs
$ 1,196,837 $ -

Table of Contents

June 2020 Note

On June 29, 2020, the Company issued a $1,811,250 principal amount senior secured convertible note (the “June 2020 Note”). At closing, $1,575,000 was funded. The principal amount is due and payable in nine equal monthly installments of $201,250 beginning four months after the funding date with the remaining balance due on the twelfth month after the date of funding. The Note is convertible at a fixed convertible price of $1.16 per share. In connection with the issuance of the June 2020 Note, the Company paid a $100,000 due diligence fee by issuing 136,575 shares to the Investor priced at $0.7322 per share. The Company also paid a placement fee of 7% of the gross proceeds to a placement agent.

In connection with the closing of the June 2020 Note, the Company issued a five-year warrant to the Investor to purchase 1,425,000 shares of common stock at a fixed exercise price of $1.16 per share, and was immediately exercisable. The Company paid a placement fee of 7% of the gross proceeds to a placement agent. The valuation of the warrant of $511,402 was recorded to debt discount and is being amortized over the life of the June 2020 Note. The fees associated with the agreement were allocated to debt issuance costs and additional paid-in capital based on the respective ratio of the valuation of the note and warrant. Amortization of the debt issuance costs and debt discount are included in interest expense on the statement of operations.

Following the completion of the underwritten offering consummated in July 2020, all outstanding amounts relating to the June 2020 Note were paid in full. As a result of the repayment, the Company expensed the remaining debt discounts and issuance costs of $957,919 in July 2020.

The June 2020 Note, net of unamortized debt issuance costs consisted of:

June 30,

December 31,

2020

2019

Principal amount
$ 1,811,250 $ -
Less: unamortized debt discount
(745,575
)
-
Less: unamortized debt issuance costs
(212,344
)
-
Notes payable, net of unamortized debt issuance costs
$ 853,331 $ -

~~11.~~13.

LEASES

The Company’s leases office space in New Jersey, Hong Kong, Minnesota, and ~~Minnesota~~New Hampshire with lease termination dates of 2023, 2020, 2022, and ~~2019,~~2022, respectively. The ~~Minnesota lease is under 12 months, thus classified as short-term and not reported on the balance sheet under ASC 842. The Hong Kong and the New Jersey~~ leases include non-lease components with variable payments. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases, ~~were:~~for the three months ended and as of:

		3 Months ended June 30,		6 Months ended June 30,				3 Months ended June 30,		6 Months ended June 30,
		2019		2019				2020		2020

Lease cost
Operating lease cost		$	42,981	$	85,962			$	53,723	$	107,445
Short-term lease cost			15,094		31,390
Sublease income			-		-
Total lease cost		$	58,075	$	117,352			$	53,723	$	107,445

Balance sheet information	Balance sheet information						Balance sheet information
Operating ROU assets	Operating ROU assets			$	532,757		Operating ROU assets			$	552,954

Operating lease liabilities, current portion	Operating lease liabilities, current portion			$	141,068		Operating lease liabilities, current portion			$	204,282
Operating lease liabilities, non-current portion	Operating lease liabilities, non-current portion				383,028		Operating lease liabilities, non-current portion				346,064
Total operating lease liabilities	Total operating lease liabilities			$	524,096		Total operating lease liabilities			$	550,346

Weighted average remaining lease term (in years) – operating leases	Weighted average remaining lease term (in years) – operating leases				3.90		Weighted average remaining lease term (in years) – operating leases				2.75
Weighted average discount rate – operating leases	Weighted average discount rate – operating leases				5.50	%	Weighted average discount rate – operating leases				5.50	%

Supplemental cash flow information related to leases were as follows, for the six months ended June 30, ~~2019:~~2020:

Cash paid for amounts included in the measurement of operating lease liabilities

~~84,231~~104,602

Maturities of operating lease liabilities were as follows:

2019 (remaining six months)	$	83,217
2020		155,682
2020 (remaining six months)				$	119,384
2021		127,425			223,377
2022		131,249			165,194
2023		89,226			89,226
Total future lease payments	$	586,799		$	597,181
Less: imputed interest		(62,703	)		(46,835	)
Total	$	524,096		$	550,346

~~In June 2019, the Company entered into a lease agreement with respect to 5,544 square feet at 1301 Corporate Center Drive, Suite 1160, Eagan, Minnesota. The term~~

Table of the lease is 36 months and will commence in September 2019. Future lease payments are approximately $129,000. On commencement of the lease the Company will record an operating ROU asset and corresponding lease liability.
Contents

~~12.~~14.

EARNINGS (LOSS) PER SHARE - COMMON STOCK (“EPS”)

The Company’s basic EPS is calculated using net loss available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of convertible ~~preferred stock.~~notes.

The reconciliation of the numerator of the basic and diluted EPS calculations was as follows for both of the following three and six month periods ended June 30, ~~2019~~2020 and ~~2018:~~2019:

Three Months ended
June 30,

Six Months ended
June 30,

2019

2018

2019

2018

Basic Numerator:

Net loss
$ (1,425,743
)
$ (1,655,465
)
$ (3,229,251
)
$ (3,847,456
)
Convertible preferred stock dividends
- (41,870
)
- (198,033
)
Net loss available to common stockholders
$ (1,425,743
)
$ (1,697,335
)
$ (3,229,251
)
$ (4,045,489
)

Three Months ended
June 30,

Six Months ended
June 30,

2020

2019

2020

2019

Basic and Diluted Numerator:

Net loss
$ (1,572,709
)
$ (1,425,743
)
$ (4,942,991
)
$ (3,229,251
)
Deemed dividends related to down-round features
- - (112,686
)
-
Net loss available to common stockholders (basic and diluted)
$ (1,572,709
)
$ (1,425,743
)
$ (5,055,677
)
$ (3,229,251
)

Items excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:

	Three Months ended June 30,				Six Months ended June 30,				Three Months ended June 30,				Six Months ended June 30,
	2019		2018		2019		2018		2020		2019		2020		2019

Stock options		1,551,349		1,366,467		1,784,183		1,445,891		1,603,054		1,551,349		1,603,054		1,784,183
Preferred stock		-		1,200,767		-		2,853,513
Warrants		3,780,976		1,398,969		3,780,976		1,398,969		5,651,889		3,780,976		5,651,889		3,780,976
Convertible notes		368,952		-		278,243		-
Total		5,701,277		3,966,203		5,843,402		5,698,373		7,254,943		5,332,325		7,254,943		5,565,159

The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the net losses for the three and six months ended June 30, ~~2019~~2020 and ~~2018:~~2019:

	Three Months ended June 30,				Six Months ended June 30,				Three Months ended June 30,				Six Months ended June 30,
	2019		2018		2019		2018		2020		2019		2020		2019

Stock options		4,071		37,015		-		19,863		1,326		4,071		748		-
Warrants										80,797		-		49,818		-
Convertible notes										3,837,165		368,952		3,837,165		278,243
Total		4,071		37,015		-		19,863		3,919,288		373,023		3,887,731		278,243

~~13.~~15.

STOCKHOLDERS’ EQUITY

Preferred Stock

Within the limits and restrictions provided in the Company’s Certificate of Incorporation, the Board of Directors has the authority, without further action by the shareholders, to issue up to 5,000,000 shares of preferred stock, $.0001 par value per share, in one or more series, and to fix, as to any such series, any dividend rate, redemption price, preference on liquidation or dissolution, sinking fund terms, conversion rights, voting rights, and any other preference or special rights and qualifications. As of June 30, ~~2019,~~2020, 100,000 shares of preferred stock have been designated as Series A-1 Convertible Preferred Stock ~~of which 90,000 were issued in 2015 and 0 remain outstanding,~~ and 105,000 shares of preferred stock have been designated as Series B-1 Convertible Preferred ~~Stock, of which 105,000 were issued in 2015 and 0 remain outstanding.~~

~~Series A-1 Convertible Preferred Stock~~

On October 22 and 29, 2015, the Company issued 84,500 shares of Series A-1 Convertible Preferred Stock at a purchase price of $100.00 per share, for aggregate gross proceeds of $8,450,000. On November 11, 2015, 5,500 additional shares of Series A-1 Convertible Preferred Stock were issued at a purchase price of $100.00 per share, for gross cash proceeds of $550,000.

~~Between September 22, 2017 and May 31, 2018, the holder of the Series A-1 Stock converted all shares of Series A-1 Stock into an aggregate of 2,500,000 shares of common~~Stock. There was no preferred stock ~~and purchased an aggregate of 248,893 shares of common stock in consideration of the conversion of $896,015 of accrued dividends payable on the Series A-1 Stock.~~

~~As a result of the forgoing conversions,~~outstanding as of June 30, ~~2019 there are no longer any issued and outstanding shares of Series A-1 Stock.~~

~~Overall balances and conversion of Series A-1 shares and accrued dividends into common stock has been as follows:~~2020 or December 31, 2019.

Series A-1

Accrued
Dividends

Balance – January 1, 2017
90,000 $ 270,000
Accrual of dividends – Q1 2017
- 135,000
Accrual of dividends – Q2 2017
- 135,000
Accrual of dividends – Q3 2017
- 135,000
Conversion into common stock – September 2017
- (540,000
)
Conversion into common stock – October 2017
(27,404
)
-
Accrual of dividends – Q4 2017
101,658
Balance – December 31, 2017
62,596 $ 236,658
Accrual of dividends – Q1 2018
- 93,894
Conversion into common stock – April 2018
(39,088
)
(330,552
)
Accrual of dividends – Q2 2018 (until final conversion)
- 25,463
Conversion into common stock – May 2018
(23,508
)
(25,463
)
Balance – December 31, 2018
- $ -

Table of Contents

~~Series B-1 Convertible Preferred Stock~~Warrants

~~On November 11, 2015, the Company issued 105,000 shares of Series B-1 Convertible Preferred Stock at a purchase price of $100.00 per share, for gross proceeds of $10,500,000.~~

Between March 23, 2018 and May 23, 2018, holders of shares of Series B-1 Stock converted all shares of Series B-1 Stock into an aggregate of 2,916,668 shares of common stock and purchased an aggregate of 131,229 shares of common stock in consideration of the conversion of $472,426 of accrued dividends payable on the Series B-1 Stock.

~~As a result of the forgoing conversions, as of June 30, 2019 there are no longer any issued and outstanding shares of Series B-1 Stock.~~

~~Overall balances and conversion of Series B-1 shares and accrued dividends into common stock has been as follows:~~

Series B-1

Accrued
Dividends

Balance – January 1, 2017
105,000 $ 131,250
Accrual of dividends – Q1 2017
- 65,625
Accrual of dividends – Q2 2017
- 65,625
Accrual of dividends – Q3 2017
- 65,625
Accrual of dividends – Q4 2017
- 65,625
Balance – December 31, 2017
105,000 393,750
Conversion into common stock – March 2018
(60,420
)
(417,084
)
Accrual of dividends – Q1 2018
- 62,268
Accrual of dividends – Q2 2018 (until final conversion)
- 16,408
Conversion into common stock – May 2018
(44,580
)
(55,342
)
Balance – December 31, 2018
- $ -

~~Common Stock~~

~~On March 21 and 28, 2019, the Company issued 13,820 shares of common stock to its directors in payment of board and board committee fees valued at $16,506.~~

~~On May 14, 2019, the Company issued 4,235 shares of common stock to its directors in payment of committee and board fees, valued at $5,505.~~

~~See Note 10 for common stock issued as commitment fees for notes payable in the quarter.~~

Securities Purchase Agreement dated November 13, ~~2014~~2014:

~~Pursuant to~~As part of a Securities Purchase Agreement, dated November 13, 2014, by and between the Company and a number of private and institutional investors, the Company issued to certain private investors ~~664,584 shares of common stock and~~ warrants to purchase ~~an additional~~ 996,877 shares of common ~~stock for aggregate gross proceeds of $1,595,000.~~stock. The warrants expired in November 2019.

The warrants have a term of five years and an initial exercise price of $3.60 per share, and have been fully exercisable since February 2015. The warrants have customary anti-dilution protections including a “full ratchet” anti-dilution adjustment provision which are triggered in the event the Company sells or grants any additional shares of common stock, options, warrants or other securities that are convertible into common stock at a price lower than $3.60 per share, The anti-dilution adjustment provision is not triggered by certain “exempt issuances” which among other issuances, includes the issuance of shares of common stock, options or other securities to officers, employees, directors, consultants or service providers.

On August 24, 2018 the Company issued Common Stock and Warrants to investors at a purchase price of $1.50 per unit which triggered the anti-dilution protection provision under this Securities Purchase Agreement. Due to this provision, the total number of outstanding and fully vested warrants was increased from 996,877 to 2,392,502, and the exercise price was reduced from $3.60 to $1.50 per share. The Company recognized a non-cash deemed dividend of $1,288,139 in 2018 in connection with these adjustments.

Securities Purchase Agreement dated September 23, ~~2015~~2015:

On September 23, 2015, the Company issued ~~a warrant~~warrants (the “2015 Warrants”) to purchase 69,445 shares of common stock in connection with the issuance of a promissory note. The warrants ~~are~~were immediately exercisable at an initial exercise price of $3.60 per share and have a term of five years.

The ~~warrants~~2015 Warrants have ~~customary anti-dilution protections including~~ a "full ratchet" anti-dilution adjustment provision which ~~are~~is triggered in the event the Company sells or grants any additional shares of common stock, options, warrants or other securities that are convertible into common stock at a price lower than $3.60 per share. The anti-dilution adjustment provision is not triggered by certain "exempt issuances" which among other issuances, includes the issuance of shares of common stock, options or other securities to officers, employees, directors, consultants or service providers.

Anti-dilution adjustments were triggered as follows:

On August 24, 2018 the Company issued warrants to certain investors which triggered the anti-dilution provisions included in the 2015 Warrants. As a result, the number of shares of common stock issuable upon the full exercise of the 2015 Warrants was increased from 69,445 to 166,668 shares, and the exercise price was reduced from $3.60 to $1.50 per share.

On February 14, 2020, the February 2020 Note was issued at a conversion price of $1.15 that triggered the anti-dilution provisions included in these warrants. In addition, the amendments to the Original Note reduced the conversion price of the Original Note to $0.65 which also triggered the anti-dilution provision of the 2015 Warrants. As a result of the forgoing transactions, the number of shares of common stock issuable upon the full exercise of the 2015 Warrants increased to 384,618, the exercise was reduced to $0.65 per share, and the Company recorded a non-cash deemed dividend in amount of $41,688.

Referral Fee:

The Company issued a warrant to an investor for 125,000 shares for a business referral valued at $94,655 during the three months ended June 30, 2020.

Common Stock

On March 21 and 28, 2019, the Company issued ~~Common Stock~~13,820 shares of common stock to its directors in payment of board and ~~Warrants~~board committee fees valued at $16,506. There were no shares of common stock issued in payment of board and board commitment fees in the three months ended March 31, 2020.

On April 2, 2020, the Company issued 6,850 shares of common stock to its directors in payment of meeting fees valued at $5,001.

On May 12, 2020, the ~~investors~~Company issued 7,077 shares of common stock to its directors in payment of meeting fees valued at ~~a purchase price~~$7,003.

On May 14, 2020, the Company issued 1,632 shares of ~~$1.50 per unit which triggered~~common stock to its directors in payment of committee meeting fees valued at $1,501.

On June 8, 2020, the ~~anti-dilution protection provision under this Securities Purchase Agreement. Due~~Company issued 1,581 shares of common stock to ~~this provision, the total number~~its directors in payment of ~~outstanding~~committee meeting fees valued at $1,502.

See Note 12 - Convertible Notes Payable for common stock issuances related to conversion of convertible notes payable and ~~fully vested warrants was increased from 69,445 to 166,668, and the exercise price was reduced from $3.60 to $1.50 per share. The Company recognized a non-cash deemed dividend~~shares of ~~$140,827 in 2018~~common stock issued for fees in connection with ~~these adjustments.~~the agreements.

Issuances of Stock Options

~~No options were granted during the quarter ended June 30, 2019. During the six months ending June 30, 2019,~~On April 2, 2020, the Company issued ~~options~~a stock option to ~~purchase 235,334~~a new employee for 5,000 shares ~~of common stock to certain officers, employees, and contractors. The options have~~with a ~~three year~~three-year vesting period, seven year term, and exercise price of ~~$1.18.~~ $0.73 per share.

The fair value of the ~~options~~option at date of issuance was estimated on the date of grant at ~~$243,643~~$2,267 using the Black-Scholes option-pricing model with the following assumptions: risk free interest rate: ~~2.35%~~0.36%, expected life of options in years: 4.5, expected dividends: 0, volatility of stock price: ~~143%~~83%.

~~14.~~

~~SEGMENT INFORMATION~~

~~The Company has determined that its continuing operations are one discrete segment consisting~~

Table of biometric products. Geographically, North American sales accounted for approximately 49% and 56% of the Company’s total sales for the three months ended June 30, 2019 and 2018, respectively, and were approximately 48% and 54% of the Company’s total sales for the six months ended June 30, 2019 and 2018, respectively.
Contents

~~15.~~16.

FAIR VALUES OF FINANCIAL INSTRUMENTS

Cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and due from factor, are carried at, or approximate, fair value because of their short-term nature. The carrying values of the convertible debt and operating lease obligation approximated their fair values as of June 30, 2020 and December 31, 2019 as the interest rates approximated market.

~~16.~~17.

MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE

For the three months ended June 30, 2020 and 2019, one customer accounted for 41% and ~~2018,~~ two customers accounted for 59% ~~and 34%~~ of revenue, respectively. For the six months ended June 30, ~~2019~~2020 and ~~2018,~~2019, three customers accounted for ~~58%~~60% and ~~two customers accounted for 37%~~58% of revenue, respectively.

~~Two~~Three customers accounted for ~~90%~~13%, 12% and 10% of current accounts receivable, respectively as of June 30, ~~2019.~~2020. At December 31, ~~2018, one customer~~2019, three customers accounted for ~~70%~~18%, 16% and 14% of current accounts ~~receivable. One customer accounted for 100% of non-current accounts~~ receivable, ~~as of June 30, 2019 and December 31, 2018, the full amount of which has been reserved for.~~respectively.

~~17.~~18.

PAYMENT PROTECTION PROGRAM TERM NOTE

On April 20, 2020, the Company entered into a Paycheck Protection Program Term Note (the “SVB Note”) with Silicon Valley Bank (“SVB”) pursuant to the Paycheck Protection Program (the “Program”) of the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration.

The Company received total proceeds of approximately $341,000 which will be used in accordance with the requirements of the CARES Act. The Company will apply to SVB for forgiveness of amounts due on the SVB Note to the extent they are used for eligible payroll costs, rent obligations, and covered utility payments incurred during the “covered period” following disbursement under the SVB Note. Until the six-month anniversary of the date of the SVB Note (the “Deferral Expiration Date”), neither principal nor interest is due and payable. On the Deferral Expiration Date, the outstanding principal of the SVB Note that is not forgiven will convert to an amortizing term loan at an interest rate of 1% per annum requiring equal monthly payments of principal and interest through November 20, 2022.

The Company has performed initial calculations for the SVB Note forgiveness according to the terms and conditions of the SBA’s Loan Forgiveness Application (Revised June 16, 2020) and, based on such calculations, expects that the SVB Note will be forgiven in full. In addition, the Company has determined that it is probable the Company will meet all the conditions of the SVB Note forgiveness. As such, the Company has decided that the SVB Note should be accounted for as a government grant which analogizes with International Accounting Standards (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance. Under the provisions of IAS 20, “a forgivable loan from government is treated as a government grant when there is reasonable assurance that the entity will meet the terms for forgiveness of the loan.” IAS 20 does not define “reasonable assurance”, however, based on certain interpretations, it is analogous to “probable” in U.S. GAAP under FASB ASC 450-20-20, which is the definition the Company has applied to its expectations of the SVB Note forgiveness. In addition, in accordance with the provisions of IAS 20, government grants shall be recognized in profit or loss on a systematic basis over the periods in which the Company recognizes costs for which the grant is intended to compensate (i.e. qualified expenses). Therefore, the Company recognized the funding during the periods when qualified expenses were incurred.

19.	SUBSEQUENT EVENTS

~~On August 8, 2019,~~Refer to Note 12 - Convertible Notes Payable for subsequent events related to the ~~Company issued 4,425 shares of common stock to its directors in payment of board fees.~~ notes.

On July ~~1, 2019, 10,000~~31, 2020, warrants were exercised for 211,000 shares of common ~~stock~~stock.

On August 12, 2020, warrants were ~~issued in connection with the monthly commitment fee~~exercised for ~~the April 4, 2019 convertible debenture.~~475,500 shares of common stock.

~~Securities Purchase Agreement dated July 10, 2019~~Underwriting agreement

On July ~~10, 2019,~~20, 2020, the Company ~~issued a $3,060,000 principal amount senior secured convertible note~~entered into an underwriting agreement (the ~~“Note”~~“Underwriting Agreement”)~~. At closing, a total of $2,550,000 was funded. The principal amount due~~ with Maxim Group LLC, as representative of the ~~Note is due~~several underwriters named therein (the “Underwriters”) with respect to the issuance and ~~payable as follows: $918,000 is due 180 days after funding, $1,071,000 is due 270 days after funding,~~sale of: (i) 29,130,000 shares (the “Shares”) of common stock, $0.0001 par value per share (“Common Stock”), (ii) pre-funded warrants to purchase 4,100,000 shares of Common Stock at an exercise price of $0.01 per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase an aggregate of 33,230,000 shares of Common Stock at an exercise price of $0.65 per share (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants” and, together with the Shares and the ~~remaining balance~~Pre-Funded Warrants, the “Securities”), in an underwritten public offering (the “Offering”) pursuant to the Underwriting Agreement.

Each Share was sold together with a Common Warrant to purchase one share of Common Stock, at a combined price to the public of $0.65 per share of Common Stock and accompanying Warrant. Each Pre-Funded Warrant was sold together with a Common Warrant to purchase one share of Common Stock, at a combined price to the public of $0.64 per Pre-Funded Warrant and accompanying Warrant.

Table of Contents

Each Pre-Funded Warrant is ~~due 12 months after~~immediately exercisable upon issuance and will expire when exercised in full. The Common Warrants have a term of five years and are immediately exercisable. If a registration statement under the ~~date~~Securities Act of ~~funding. Upon~~1933, as amended (the “Securities Act”), registering the ~~occurrence of standard and customary events of default and expiration of any applicable cure periods, repayment~~issuance of the ~~outstanding principal amount due~~shares of Common Stock underlying the Common Warrants is not effective or available and an exemption from registration under the ~~Note~~Securities Act is not available for the issuance of such shares, the holders of the Common Warrants may, in their sole discretion, elect to exercise their Common Warrants through a cashless exercise. The exercise of the Common Warrants is subject to ~~acceleration~~certain beneficial ownership limitations. The warrants were issued pursuant to the terms of a warrant agency agreement between the Company and Broadridge Issuer Solutions, Inc., as warrant agent.

Pursuant to the Underwriting Agreement, the Company granted the Underwriters a 45-day option to purchase up to an additional 4,984,500 shares of Common Stock and/or 4,984,500 Warrants to cover over-allotments, if any (the “Over-Allotment”). On July 21, 2020, the Underwriter exercised its Over-Allotment option in full on both the Common Stock and the Warrants.

Pursuant to the Underwriting Agreement, the Company paid the Underwriter a cash fee equal to 8% of the aggregate gross proceeds sold in the ~~discretion~~Offering and also agreed to reimburse the Underwriter for reasonable out-of-pocket expenses related to the Offering, including the reasonable fees and expenses of counsel to the ~~Investor~~Underwriters, in ~~which event, interest will accrue at~~ the ~~higher of 18% per annum or the~~aggregate maximum amount ~~permitted by applicable law and the Company will become obligated~~of up to ~~pay an amount equal to 20% of the then outstanding principal amount due under the Note.~~ $80,000.

The ~~Note is secured~~Underwriting Agreement contains customary representations, warranties and agreements by ~~a lien on substantially all of our assets and properties and is convertible at~~ the ~~option~~Company, customary conditions to closing, indemnification obligations of the ~~Investor into shares~~Company and the Underwriters, including for liabilities under the Securities Act, other obligations of ~~our common stock~~the parties and termination provisions. The representations, warranties and agreements made by the parties in the Underwriting Agreement were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties, and should not be deemed to be a representation, warranty or agreement to or in favor of any party. In addition, the assertions embodied in any representations, warranties and agreements contained in the Underwriting Agreement may be subject to qualifications with respect to knowledge and materiality different from those applicable to security holders generally. Moreover, such representations, warranties and agreements should not be relied on as accurately representing the current state of the Company’s affairs at ~~a fixed conversion price of $1.50 per share.~~any time.

The Securities were offered by the Company pursuant to an effective registration statement on Form S-1, as amended, which was originally filed with the Securities and Exchange Commission on July 9, 2020, and was declared effective on July 20, 2020 (File No. 333-239782) (the “Registration Statement”), and registration statement on Form S-1MEF (File No. 333-239966). The Company ~~has~~filed a final prospectus with the ~~right to prepay the Note~~SEC on July 22, 2020 in ~~full at any time without penalty in which event, the Investor will have the option of converting 25% of the outstanding principal amount of the Note into shares of our common stock. .~~

In connection with the ~~closing,~~sale of the Securities.

The Offering and the Over-Allotment option closed on July 23, 2020. The net proceeds of the Offering including the full exercise of the Over-Allotment were approximately $22.8 million, after deducting the underwriting discounts and commissions and estimated offering expenses. The Company ~~issued a five year warrant~~used approximately $4.2 million of the net proceeds of the Offering to ~~the Investor to purchase 2,000,000~~satisfy all outstanding amounts due under convertible promissory notes previously issued. The prefunded warrants were exercised on July 23, 2020 and July 27, 2020 resulting in an increase of common stock of 4,100,000 shares. Total shares of common stock ~~at a fixed exercise price~~outstanding increased by 38,214,500 for the underwriting transaction through date of ~~$1.50 per share and paid a $50,000 commitment fee, and issued 266,667 shares of common stock in payment of a $400,000 due diligence fee.~~this report.

~~Until~~Nasdaq Capital Market listing requirements

On May 18, 2020 the ~~second anniversary~~Company received a notice (the “Notice”) from the Staff of the ~~closing,~~Listing Qualifications Department (the “Staff”) of The Nasdaq Capital Market LLC (“Nasdaq”) indicating the ~~Investor has~~Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) because, the ~~right~~Company did not have a minimum of $2,500,000 in stockholders’ equity for continued listing on Nasdaq (the “Stockholders’ Equity Requirement”). On July 10, 2020, the Company’s plan to ~~purchase up~~regain compliance with the Stockholders’ Equity Requirement previously submitted to ~~20%~~the Nasdaq was accepted and Nasdaq granted us an extension of 180 calendar days from the date of the ~~securities we issue~~Notice (November 16, 2020) for to provide evidence of compliance.

As discussed above , on July 23, 2020, the Company completed an underwritten public offering resulting in ~~any future private placement,~~net cash proceeds of approximately $22.8 million which was used, in part, to repay approximately $4.2 million of outstanding convertible promissory notes. Accordingly, as of the date of this report the Company believes that it has satisfied compliance with the Stockholders’ Equity Requirement and has been advised that Nasdaq will continue to monitor the Company’s ongoing compliance with the Stockholders’ Equity Requirement and, if at the time of the Company’s next periodic report the Company does not evidence compliance, that it may be subject to ~~certain exceptions for, among other things, strategic investments.~~delisting.

Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

All statements other than statements of historical facts contained in this Report on Form 10-Q, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Although we believe that our plans, intentions and expectations reflected in the forward-looking statements are reasonable, we cannot be sure that they will be achieved. Particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition between us and other companies in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to execute and deliver on contracts in Africa, our ability to expand into Asia, Africa and other foreign markets; the duration and severity of the current coronavirus COVID-19 pandemic and its effect on our business operations, sales cycles, personnel, and the geographic markets in which we operate; delays in the development of products and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (the “SEC”) and other filing with the SEC. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing. Except as required by law, we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

~~CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS~~

~~All statements other than statements~~This Management’s Discussion and Analysis of ~~historical facts contained in this Report on Form 10-Q, including statements regarding our future financial position, business strategy~~Financial Condition and ~~plans and objectives~~Results of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Although we believe that our plans, intentions and expectations reflected in the forward-looking statements are reasonable, we cannot be sure that they will be achieved. Particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition between us and other companies in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to expand into the Asian market; delays in the development of products and statements of assumption underlying any of the foregoing, as well as other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing. Except as required by law, we undertake no obligation to update or revise any forward-looking statement, whetherOperations is provided as a ~~result of new information, future events or otherwise.~~

The following discussion and analysis summarizes the significant factors affecting the operating results, financial condition, liquidity and cash flows of our Company as of and for the periods presented belowsupplement to and should be read in conjunction with our unaudited condensed consolidated financial statements and related information contained herein and in our audited financial statements as of December 31, ~~201~~8.2019.

OVERVIEW

BIO-key International, Inc. (the ~~“Company”~~“Company”, ~~“we”~~“we” or ~~“us”~~“us”) develops and ~~markets~~market advanced fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing fingerprint biometric hardware and software solutions. We were pioneers in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as ~~personal inspection identification,~~ passwords, tokens, keys, smart ~~cards, ID~~ cards, PKI, credit card, passports, driver’s licenses, OTP or other ~~form~~forms of possession or knowledge-based credentialing. Advanced ~~BIO-key~~BIO-key® technology has been and is used to improve both the accuracy and speed of competing finger-based biometrics. Our solutions are used by ~~many~~ customers in every sector of our economy including government, financial services, education, manufacturing, retail, ~~healthcare~~ and ~~financial services.~~call centers.

~~In partnerships with OEMs, integrators, and solution providers, we provide biometric software solutions to private and public sector customers.~~ We provide the ability to positively identify and authenticate individuals before granting access to valuable corporate resources, web portals or applications in seconds. Powered by our patented Vector Segment Technology (VST™), ~~or VST, WEB-key~~WEB-key® and BSP development kits are fingerprint biometric solutions that provide interoperability with ~~all major~~dozens of reader manufacturers, enabling application developers and integrators to integrate fingerprint biometrics into their applications.

Our biometric identification technology improves both the accuracy and speed of screening individuals, for identification purposes or for personal identity verification, by extracting unique data from a fingerprint and comparing it to existing similar fingerprint data. The technology has been built to be scalable and to handle databases containing millions of fingerprints. We achieve the highest levels of discrimination without requiring any other identifying data (multi-factor) such as a user ID, smart cards, or tokens, although our technology can be used in conjunction with such additional factors. Users of our technology have the option of on device or cloud authentication. This flexible authentication option in conjunction with our interoperable capabilities, is another key differentiator of our biometric identification solutions.

Our WEB-key solution is a client server suite that can be integrated into virtually any application, whether web based or desktop application based on Windows. The WEB-key solution is a security solution that protects the biometric data in processing, transmission and storage. WEB-key provides a turn-key solution for biometric as well as multi-factor authentication across an enterprise, government system or any user population.

We also develop and distribute hardware components that are used in conjunction with our software, and sell third-party hardware components with our software in various configurations required by our customers. Our products are interoperable with ~~all~~ major fingerprint reader and hardware manufacturers, ~~and across~~supporting Windows, Linux, Mac OS X, and ~~the~~ Android ~~mobile~~ operating systems enabling application developers, value added resellers, and channel partners to integrate our fingerprint biometrics into their applications, while dramatically reducing maintenance, upgrade and life-cycle costs. This interoperability is unique in the industry, and a key differentiator for our products in the biometric market. In our opinion, these features make our technology more viable than competing technologies and expands the size of the overall market for our products.

Table of Contents

In partnerships with OEMs, VARs, integrators, and solution providers, we market and sell biometric hardware and software solutions to SMBs, the Fortune 500 and government agencies.

We support industry standards, ~~such as FIDO,~~including PIV, FIPS, ANSI, ISO, SAML, and BioAPI ~~and~~among others. We have received National Institute of Standards and Technology (NIST) independent laboratory testing and certification of our ability to support Homeland Security Presidential Directive #12 (HSPD-12) and ANSI/INCITS-378 templates, as well as validation of our fingerprint match speed and accuracy in large database environments.

We have developed what we believe is the most discriminating and effective commercially available finger-based biometric technology. Our primary focus is in marketing and selling this technology ~~into commercial logical~~to customers seeking to secure access to networks, applications and ~~physical privilege entitlement & access control markets.~~data on-premises or remotely. Our primary market focus includes, ~~among others, enterprise access, mobile payments & credentialing, online payments, and healthcare record and payment data security. Our secondary focus includes~~ government, financial services, education, healthcare, manufacturing, retail, and ~~educational markets.~~call centers.

Products

~~In 2016, we began~~We also offer a full line of easy to ~~sell~~use finger scanners for both enterprise and consumer markets. Our SideSwipe®, SideTouch® and EcoID® scanners are plug and play compatible with Microsoft Windows and our Q-180 Touch reader is a Micro USB compatible fingerprint reader for Android devices. The readers are currently sold in the Microsoft stores, as well as through ~~distribution~~their on-line channel, on Amazon, and ~~directly to consumers and commercial users~~through our SideSwipe, SideTouch and EcoID products. SideSwipe, SideTouch and EcoID are stand-alone fingerprint readers that can be used on any laptop, tablet or other device with a USB port. In 2017, we expanded our consumer product line to include biometric and blue tooth enabled pad locks, TSA approved luggage locks, and bicycle locks.website. In 2018, we introduced OmniPass Consumer, a secure biometric-enabled application to manage multiple passwords for online apps, services, or accounts.

In 2015, Microsoft announced native support for biometrics in the Windows 8.1 and Windows 10 Operating platforms as well as Office 2016. With Microsoft Hello, any user can replace their PIN or password to access their device without any special software downloads by using our finger scanners, SideSwipe, SideTouch and EcoID, which are plug and play compatible with the Microsoft platforms. We have been the preferred partner, in particular at the Microsoft “Ignite your Business” Windows 10 and Office 2016 launch events, which has generated a number opportunities for both our hardware and software offerings. In 2016, our finger scanners were tested and qualified by Microsoft, then introduced and are sold in the Microsoft stores nationwide, as well as through their on-line channel. events.

~~In 2018, we continued~~Finally, our ID Director for Windows and ID Director for SAML offer biometric authentication to ~~invest~~SAML enables apps such as Office 365, GoToMeeting, Zoom, SalesForce, Google G-Suite, and ~~grow our relationship with Microsoft. The 2018 Ignite your Business event included Microsoft hosting an exclusive BIO-key demonstration kiosk within their event showcase.~~many others.

~~STRATEGIC OUTLOOK AND RECENT DEVELOPMENTS~~Strategic Outlook and Recent Developments

Historically, our largest market has been access control within highly regulated industries such as government, financial services, and healthcare. ~~However,~~During 2019, we ~~believe~~became the ~~mass adoption~~go-to biometric authentication provider for board of ~~advanced smart-phone~~election offices as eight offices deployed our hardware and ~~hand-held wireless devices have caused commercial demand for advanced user~~software to secure internal access to the voter registration database. We will seek to extend this footprint in 2020 and beyond.

Working with our partner TTI, we expect to begin deploying several large-scale identity and access projects in the second quarter of 2020. We are in the process of establishing an African subsidiary, to work closely with TTI who was awarded contracts of $45M and $30M. One of the Company’s board members is the Chief Executive Officer of TTI. Under the first contract, we will provide biometric authentication to ~~emerge as viable.~~support the infrastructure of a new e-commerce project developed with the expectation to generate more than one million jobs in Nigeria. The ~~introduction~~second contract provides for BIO-key hardware and software to be used by a leading African telecommunications company to secure internal access to customer data. Based on information available today, Africa and the surrounding regions are receiving government funding to expand the use of ~~smart-phone capabilities, like mobile payments~~biometric authentication solutions to help establish trustworthy government programs and ~~credentialing, could effectively require biometric user authentication on mobile devices~~reduce fraud. As described above, the COVID-19 pandemic has and may continue to ~~reduce risks~~delay the rollout of ~~identity theft, payment fraud and other forms of fraud~~these programs.

We plan to have a more significant role in the ~~mobile or cellular based world wide web. As~~Identity and Access Management (IAM) market which continues to expand. We plan to offer customers a suite of authentication options that complement our biometric solutions. The more ~~services and payment functionalities, such as mobile wallets and near field communication (NFC), migrate~~well-rounded offerings of authentication options will allow customers to ~~smart-phones, the value and potential risk associated with such systems should grow and drive demand and adoption of advanced user~~customize their approach to authentication ~~technologies, including fingerprint biometrics and BIO-key solutions.~~ all under one umbrella.

As devices with onboard fingerprint sensors continue to deploy to consumers, we expect that ~~third party~~third-party application developers will demand the ability to authenticate users of their respective applications ~~(app’s)~~(apps) with the onboard fingerprint biometric. We further believe that authentication will occur on the device itself for potentially low-value, and therefore low-risk, use-transactions and that user authentication for high-value transactions will migrate to the application provider’s authentication server, typically located within their supporting technology infrastructure, or ~~Cloud.~~cloud. We have developed our technology to enable, on-device authentication as well as network or cloud-based authentication and believe we may be the only technology vendor capable of providing this flexibility and capability.

Our core technology works on ~~over 40~~major commercially available fingerprint readers, across ~~both~~ Windows and Linux, ~~platforms,~~Mac OS X and ~~Apple iOS and~~ Android ~~mobile~~ operating systems. This interoperability, coupled with the ability to ~~authentic~~authenticate users via the device or cloud, is unique in the industry, provides a key differentiator for us, and in our opinion, makes our technology more viable than competing technologies and expands the size of the overall market for our products.

In June 2020, we expanded our business though the acquisition of PistolStar. PistolStar has over 200 active customer subscribers to their products, which include PortalGuard multi-factor authentication (MFA), Nebula identity-as-a-service (IDaaS), PortalGuard single sign-on (SSO) and PortalGuard self-service password reset (SSPR).

PistolStar’s PortalGuard MFA offers customers flexible policy-driven choices among 15 different methods of authentication, including BIO-key biometrics, FIDO U2F/2FA tokens, WebAuthn, Windows Hello, Google Authenticator, Microsoft Authenticator, RSA SecureID, Phone Push, OTP, SMS, phone-call, and bar-code, so every user can always be securely authenticated with whichever factor is most appropriate. For enterprises with existing IAM platforms, PortalGuard can be seamlessly integrated to add its complete MFA by supporting SAML, OpenID Connect, OAuth, WS-Federation, CAS, and Shibboleth, among other standards.

Table of Contents

Combining PistolStar’s proprietary authentication software with our biometric solutions creates an integrated turn-key multi-factor solution which we believe is unparalleled in the industry, and will allow BIO-key to provide a unified MFA solution that is differentiated in the market by our biometric user experience and who-you-are strong authentication.

We believe there is potential for significant market growth in the following key areas:

●	Corporate network access control, corporate campuses, computer networks, and applications.
	●	Large scale identification projects, especially in Africa and the surrounding regions.
●	Government funded initiatives, including with the state board of elections.

●	International ~~government~~law enforcement use case applications as prospects see us as a global leader in the biometric technology space as witnessed by our agreement with the Israeli Defense Force, and the Singapore and Dubai Police departments.

	●	Consumer mobile credentialing, including mobile payments, credit and payment card programs, data and application access, and commercial loyalty programs.

	●	Demand for BIO-key hardware products from Windows 10 users and Fortune 500 companies.

	●	Government services and highly regulated industries including, Medicare, Medicaid, Social Security, Drivers Licenses, Campus and School ID, Passports/Visas.

	●	~~Growth~~Continued growth in the Asia Pacific region.

	●	~~Biometric based consumer products.~~New remote authentication challenges – which our solutions are ideally suited to address.
	●	New opportunity to market remote security solutions which have been accelerated due to the COVID-19 pandemic.

In the near-term, we expect to grow our business within government services and highly-regulated industries ~~such as healthcare and financial services industry.~~in which we have historically had a strong presence. We believe that continued heightened security and privacy requirements in these industries will generate increased demand for security solutions, including biometrics. In addition, we expect that the integration of our technology into Windows 10, will accelerate the demand for our computer network log-on solutions and fingerprint readers. ~~Finally, our entry~~

Our two primary sales strategies call for expanded marketing efforts into the ~~Asian~~IAM market ~~has further expanded our business by opening new markets~~ along with a dedicated pursuit of large-scale identification projects across the new and innovative hardware offerings. We expect our SideSwipe, EcoID and SideTouch finger readers, and our biometric and Bluetooth enabled bicycle locks to continue to drive incremental revenue and growth. globe.

We ~~intend~~also plan on expanding our new Channel Alliance Program which now has more than twenty participants and started to expand our business into the cloud and mobile computing industries. The emergence of cloud computing and mobile computing are primary drivers of commercial and consumer adoption of advanced authentication applications, including biometric and BIO-key authentication capabilities. As the value of assets, services and transactions increases on such networks, we expect that security and user authentication demand should rise proportionately. Our integration partners include major web and network technology providers, who we believe will deliver our cloud-applicable solutions to interested service-providers. These service-providers could include, but are not limited to, financial institutions, web-service providers, consumer payment service providers, credit reporting services, consumer data service providers, healthcare providers and others. Additionally, our integration partners include major technology component providers and OEM manufacturers, who we believe will deliver our device-applicable solutions to interested hardware manufacturers. Such manufacturers could include cellular handset and smartphone manufacturers, tablet manufacturers, laptop and PC manufacturers, among other hardware manufacturers. Our recently introduced SAML and Open ID solutions will create new opportunities for us in 2019. generate modest initial revenues.

~~CRITICAL ACCOUNTING POLICIES~~Impact of COVID-19

In March 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, and, in the following weeks, many U.S. states and localities issued lockdown orders impacting our operations. Since then, the COVID-19 situation within the U.S. has rapidly escalated and has severely restricted the level of economic activity around the world. The COVID-19 outbreak has caused us to migrate to a remote business model for our sales, marketing, administrative and executive teams. Research and development and production are adjusting to the new landscape to maintain production as best as possible considering the conditions and regulations. We continue to monitor the situation closely and it is possible that we will implement further measures. Since we qualify as an essential business in New Jersey because we serve the healthcare industry, we have been able to access inventory to fulfill orders and ship products as required. The pandemic has extended sales cycles and delayed deployments in most markets in which we operate, particularly in Africa which remains subject to shut-down and shelter at home orders. We continue to conduct business daily and are actively closing transactions throughout the current climate, with no changes to personnel.

The complications caused by the pandemic have forced organizations to quickly adapt to a work from home remote business model. This increases the risk of unauthorized users, phishing attacks, and hackers eager to take advantage of the challenges of securing remote workers. We believe that biometrics should play a key role in remote user authentication.

Critical Accounting Policies

For detailed information regarding our critical accounting policies and estimates, see our financial statements and notes thereto included in this Report and in our Annual Report on Form 10-K for the year ended December 31, ~~2018.~~2019. There have been no material changes to our critical accounting policies and estimates from those disclosed in our most recent Annual Report on Form ~~10-K, except for adoption of Leases (ASC 842) – refer Note 1.~~10-K.

~~RECENT ACCOUNTING PRONOUNCEMENTS~~Recent Accounting Pronouncements

For detailed information regarding recent account pronouncements, see Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

Table of Contents

RESULTS OF OPERATIONS

THREE MONTHS ENDED JUNE 30, ~~201~~20920 AS COMPARED TO JUNE 30, 20189

Consolidated Results of Operations - Percent Trend

Three Months Ended June 30,

2019

2018

Revenues

Services
32
%
33
%
License fees
8
%
21
%
Hardware
60
%
46
%
Total Revenues
100
%
100
%
Costs and other expenses

Cost of services
8
%
16
%
Cost of license fees
51
%
102
%
Cost of hardware
34
%
19
%
Total Cost of Goods Sold
93
%
138
%
Gross profit (loss)
7
%
-38
%

Operating expenses

Selling, general and administrative
145
%
144
%
Research, development and engineering
41
%
40
%
Total Operating Expenses
187
%
184
%
Operating loss
-180
%
-221
%

Other income (expense)
-16
%
0
%

Net loss
-196
%
-221
%

Three Months Ended June 30,

2020

2019

Revenues

Services
75
%
32
%
License fees
8
%
8
%
Hardware
17
%
60
%
Total Revenues
100
%
100
%
Costs and other expenses

Cost of services
30
%
8
%
Cost of license fees
3
%
51
%
Cost of hardware
15
%
34
%
Total Cost of Goods Sold
48
%
93
%
Gross profit (loss)
52
%
7
%

Operating expenses

Selling, general and administrative
395
%
145
%
Research, development and engineering
104
%
41
%
Total Operating Expenses
498
%
187
%
Operating loss
-447
%
-180
%

Other income (expense)
-65
%
-16
%

Net loss
-512
%
-196
%

Revenues and cost of goods sold

Three months ended
June 30,

Three months ended
June 30,

2019

2018

$ Change

% Change

2020

2019

$ Change

% Change

Revenues

Service
$ 231,993 $ 249,121 $ (17,128
)
-7
%
$ 229,503 $ 231,993 $ (2,490
)
-1
%
License
60,300 154,251 (93,951
)
-61
%
23,542 60,300 (36,758
)
-61
%
Hardware
436,090 344,769 91,321 26
%
54,097 436,090 (381,993
)
-88
%
Total Revenue
$ 728,383 $ 748,141 $ (19,758
)
-3
%
$ 307,142 $ 728,383 $ (421,241
)
-58
%

Three months ended
June 30,

Three months ended
June 30,

2019

2018

$ Change

% Change

2020

2019

$ Change

% Change

Cost of Goods Sold

Service
$ 58,421 $ 120,841 $ (62,420
)
-52
%
$ 92,672 $ 58,421 $ 34,251 59
%
License
372,327 766,637 (394,310
)
-51
%
8,255 372,327 (364,072
)
-98
%
Hardware
248,678 142,325 106,353 75
%
47,527 248,678 (201,151 ) -81
%
Total COGS
$ 679,426 $ 1,029,803 $ (350,377
)
-34
%
$ 148,454 $ 679,426 $ (530,972
)
-78
%

Revenues

For the three months ended June 30, ~~2019~~2020 and ~~2018,~~2019, service revenues included approximately ~~$229,000~~$205,000 and ~~$241,000,~~$229,000, respectively, of recurring maintenance and support revenue, and approximately ~~$3,000~~$25,000 and ~~$8,000~~$3,000 respectively, of non-recurring custom services revenue. Recurring service revenue decreased 5%$24,000 or 11% in ~~2019~~2020 as ~~some of~~ the ~~current renewals are pending.~~SaaS orders carry smaller annual renewal fees. Non-recurring custom services ~~decreased $5,000 or 63%~~increased $22,000 for custom services due to ~~fewer~~one customized ~~installations.~~software enhancement for an existing customer.

For the three months ended June 30, ~~2019,~~2020, license revenue decreased 61% from the corresponding period in ~~2018.~~2019. The lower revenue was the result of deploying more subscription based orders than perpetual license ~~orders.~~orders, in addition to the adverse effects to the sales pipeline caused by the COVID-19 pandemic.

For the three months ended June 30, ~~2019,~~2020, hardware sales ~~increased~~decreased by ~~26% as a result of large order~~88%. The decrease resulted from an ~~existing customer~~approximate $7,000 or 99% reduction in ~~addition~~the shipment of locks and an approximate $375,000 or 87% reduction in shipments of fingerprint readers due to ~~several new customer deployments.~~smaller orders in 2020 as compared to 2019, and the impact of the COVID-19 pandemic.

28
Table of Contents

Costs of goods sold

For the three months ended June 30, ~~2019,~~2020, cost of service ~~decreased 52%, due~~increased approximately $34,000 or 59% to ~~changes in~~$92,672 as a result of increased support ~~personnel~~required for ~~maintenance services.~~
~~License costs~~customized software for an existing customer, compared to the three months ended June 30, 2019 where costs were reclassified from research and development resources to cost of goods sold as needed. For the three months ended June 30, 2020, license fees decreased ~~approximately 51%, which was directly associated with the amortization of the software rights due~~ to ~~change in amortization methodology.~~
~~Hardware costs for~~$8,255 from $372,327 during the three months ended June 30, 2019, ~~increased~~due largely to a decrease of approximately ~~75%, due~~$281,000 in amortization of software rights which is included in cost of license fees. For the three months ended June 30, 2020, hardware costs decreased to $47,527 from $248,678 during the ~~increase in~~three months ended June 30, 2019, related to lower costs associated with less hardware ~~revenue and the product mix.~~revenue.

Selling, general and administrative

Three months ended
June 30,

2019

2018

$ Change

% Change

Selling, general and administrative
$ 1,058,671 $ 1,076,184 $ (17,513 ) -2
%

Three months ended
June 30,

2020

2019

$ Change

% Change

Selling, general and administrative
$ 1,211,928 $ 1,058,671 $ 153,257 14
%

Selling, general and administrative costs for the three months ended June 30, 2019 ~~decreased -2%~~increased 14% from the corresponding period in ~~2018.~~2019. The ~~decrease~~increase is attributable to non-cash warrant issuance costs of approximately $95,000 for professional services, and personnel restructuring charges related to in our Hong Kong operations, offset by the reduction in ~~payroll and~~ non-cash compensation, ~~offset by increased~~ factoring ~~fees.~~fees, and shareholder relations expenses due to our annual meeting occurring in Q2 2019 and in Q3 2020.


Research, development and engineering

Three months ended
June 30,

2019

2018

$ Change

% Change

Research, development and engineering
$ 301,217 $ 297,633 $ 3,584 1
%

Three months ended
June 30,

2020

2019

$ Change

% Change

Research, development and engineering
$ 318,573 $ 301,217 $ 17,356 6
%

For the three months ended June 30, ~~2019,~~2020, research, development and engineering costs increased 1%6% as compared to the corresponding period in ~~2018,~~2019, as a result of decreased expenses in ~~the~~our Hong Kong subsidiary and non-cash compensation, offset by increased ~~recruiting~~personnel and related expenses.

Other income (expense)

Three months ended

June 30,

2020

2019

$ Change

% Change

Other income (expense)
$ (200,896
)
$ (114,812
)
$ (86,084
)
75
%
Other income (expense) for the 2020 related to approximately $567,000 of interest expense, which included the amortization of a beneficial conversion feature, and amortization of debt discounts and debt issuance costs relating to the convertible notes, partially offset by amounts expended under the Payment Protection Program of approximately $341,000 and interest income of approximately $26,000. The amounts for the three months ended June 30, 2019 related solely to interest expense on convertible notes.
29
Table of Contents

SIX MONTHS ENDED JUNE 30, ~~201~~20920 AS COMPARED TO JUNE 30, 20189

Consolidated Results of Operations - Percent Trend

Six Months Ended June 30,

Six Months Ended June 30,

2019

2018

2020

2019

Revenues

Services
37
%
35
%
53
%
37
%
License fees
11
%
16
%
31
%
11
%
Hardware
52
%
49
%
16
%
52
%
Total Revenues
100
%
100
%
100
%
100
%
Costs and other expenses

Cost of services
12
%
17
%
20
%
12
%
Cost of license fees
58
%
97
%
2
%
58
%
Cost of hardware
30
%
25
%
11
%
30
%
Total Cost of Goods Sold
100
%
139
%
33
%
100
%
Gross profit (loss)
-
%
-39
%
67
%
-
%

Operating expenses

Selling, general and administrative
190
%
160
%
313
%
190
%
Research, development and engineering
53
%
43
%
79
%
53
%
Total Operating Expenses
243
%
203
%
392
%
243
%
Operating loss
-243
%
-242
%
-324
%
-243
%

Other income
-9
%
0
%
Other income (expense)
-271
%
-9
%

Net loss
-252
%
-242
%
-596
%
-252
%

Revenues and cost of goods sold

Six months ended
June 30,

2019

2018

$ Change

% Change

Revenues

Service
473,603 551,570 (77,967
)
-14
%
License
143,508 256,970 (113,462
)
-44
%
Hardware
662,895 781,056 (118,161
)
-15
%
Total Revenue
$ 1,280,006 $ 1,589,596 $ (309,590
)
-19
%

Cost of Goods Sold

Service
149,250 275,573 (126,323
)
-46
%
License
749,543 1,540,102 (790,559
)
-51
%
Hardware
384,683 393,573 (8,890
)
-2
%
Total COGS
$ 1,283,476 $ 2,209,248 $ (925,772
)
-42
%

Six months ended
June 30,

2020

2019

$ Change

% Change

Revenues

Service
437,026 473,603 (36,577
)
-8
%
License
258,887 143,508 115,379 80
%
Hardware
133,714 662,895 (529,181
)
-80
%
Total Revenue
$ 829,627 $ 1,280,006 $ (450,379
)
-35
%

Cost of Goods Sold

Service
163,117 149,250 13,867 9
%
License
18,711 749,543 (730,832
)
-98
%
Hardware
90,889 384,683 (293,794
)
-76
%
Total COGS
$ 272,717 $ 1,283,476 $ (1,010,759
)
-79
%

Revenues

For the six months ended June 30, ~~2019~~2020 and ~~2018,~~2019, service revenues included approximately ~~$468,000~~$410,000 and ~~$442,000,~~$468,000, respectively, of recurring maintenance and support revenue, and approximately ~~$6,000~~$27,000 and ~~$110,000,~~$6,000, respectively, of non-recurring custom services revenue. Recurring service revenue ~~increased 6%~~decreased 12% from ~~2018~~2019 as we ~~continued~~increased deploying SaaS orders which carry smaller annual renewal fees, and some legacy renewals have been delayed due to ~~bundle maintenance agreements with our expanding customer license base and renewed existing maintenance agreements from our legacy customers.~~COVID-19. Non-recurring custom services ~~decreased 95% for custom services~~increased 370% due to the completion of aone customized software ~~project in 2018.~~enhancement for an existing customer.

For the six months ended June 30, ~~2019,~~2020, license revenue ~~decreased~~increased as a result of increased renewals and deploying more subscription ~~based orders than perpetual license orders.~~licenses.

For the six months ended June 30, ~~2019,~~2020, hardware sales decreased by ~~15%~~80%, as a result of smaller new customer deployments and decreased lock orders. Additionally, renewals of SaaS orders usually will not order additional software, unless they are expanding their deployment.

30
Table of Contents

Costs of goods sold

For the six months ended June 30, ~~2019,~~2020, cost of service ~~decreased 46%,~~increased approximately $14,000 or 9% to approximately $163,000 as a result of ~~no large custom services orders~~increased support required for customized software for an existing customer, compared to the six months ended June 30, ~~2018~~2019 where costs were reclassified from research and ~~the inclusion in~~development to cost of goods sold ~~of outside contractor costs.~~
~~License costs for~~as needed. For the six months ended June 30, 2020, license fees decreased to $18,711 from $749,543 during the six months ended June 30, 2019, ~~decreased~~largely due to decrease of approximately ~~51%, which was directly associated with the~~$562,000 in amortization of software rights. For the ~~software rights due~~six months ended June 30, 2020, hardware costs decreased to ~~change in amortization methodology.~~
~~Hardware costs for~~$90,889 from $384,683 during the six months ended June 30, 2019, ~~decreased approximately 2%. The decrease was~~due to lower costs associated with ~~the lower~~less hardware revenue, ~~to date as well as the~~and product mix.

Selling, general and administrative

Six months ended
June 30,

2019

2018

$ Change

% Change

Selling, general and administrative
$ 2,435,704 $ 2,538,038 $ (102,334 ) -4
%

Six months ended
June 30,

2020

2019

$ Change

% Change

Selling, general and administrative
$ 2,593,327 $ 2,435,704 $ 157,623 6
%

Selling, general and administrative costs for the six months ended June 30, ~~2019 decreased 4%~~2020 increased 6% from the corresponding period in ~~2018.~~2019. The ~~decrease was~~increase is attributable to ~~decreased payroll,~~non-cash warrant issuance costs of approximately $95,000, professional services, and personnel restructuring charges related to our Hong Kong operations, offset by the reduction in non-cash compensation, ~~costs~~factoring fees, and ~~legal fees, offset by increased trade show expenses and shareholder relations expense.~~ tradeshow expenses.
Research, development and engineering

Six months ended
June 30,

2019

2018

$ Change

% Change

Research, development and engineering
$ 675,335 $ 689,787 $ (14,452
)
-2
%

Six months ended
June 30,

2020

2019

$ Change

% Change

Research, development and engineering
$ 655,462 $ 675,335 $ (19,873
)
-3
%

For the six months ended June 30, ~~2019,~~2020, research, development and engineering costs decreased 2%3% from the corresponding period in ~~2018,~~2019, as a result of decreased personnel and related costs and non-cash compensation costs which amounts were offset by an increase in ~~recruiting~~contractor expenses.

Other income (expense)

Six months ended

June 30,

2020

2019

$ Change

% Change

Other income (expense)
$ (2,251,112
)
$ (114,742
)
$ (2,136,370
)
1,862
%
Other income (expense) for the 2020 period related to the interest expense, which included the amortization of a beneficial conversion feature, and amortization of debt discounts and debt issuance costs relating to the convertible notes of approximately $2,119,000, a loss on the extinguishment of a convertible debt financing in an approximate amount of $500,000, partially offset by amounts received under the Payment Protection Program of approximately $341,000 and interest income of approximately $26,000. The 2019 amounts related solely to interest expense on convertible notes.

31
Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

Cash Flows

Net cash used by operations during the six months ended June 30, ~~2019~~2020 was approximately ~~$256,000. The cash used by operating activities was attributable primarily to the following items:~~$1,970,000. Items of note included:

●
Net positive cash flows related to adjustments for non-cash expenses for depreciation, amortization, share-based and warrant based compensation, debt discounts and issuance costs, loss on extinguishment of debt, the amortization of a beneficial conversion feature, non-cash interest expense, and issuance of common stock to our non-employee directors, of approximately ~~$1,405,000, and a decrease in accounts receivable, combined with increases in accounts payable, accruals and deferred revenue of approximately $1,674,000.~~$3,492,000.

●
Net negative cash flows related to ~~reductions due from factor~~accounts payable, accruals and operating lease liabilities of approximately ~~$148,000.~~$582,000.

Approximately ~~$30,000~~$1,906,000 was used for investing activities during the six months ended June 30, 2019 related primarily to ~~capital expenditures.~~the acquisition of PistolStar. An additional $3,000 used was related to net proceeds and purchases of investments.

Approximately ~~$650,000~~$4,683,000 was provided by financing activities during the six months ended June 30, ~~2019 relating to approximately $667,000 of proceeds~~2020 from the issuance of ~~debentures, offset by approximately $17,000 in legal costs.~~ convertible notes, less fees, and exercise of warrants and net of repayments of a convertible note payable and related party loans.

At June 30, ~~2019,~~2020, we had negative net working capital of approximately ~~$1,100,000~~$2,338,000 as compared to negative net working capital of approximately ~~$3,300,000~~$3,000,000 at December 31, ~~2018.~~2019.

Liquidity and Capital Resources

Since our inception, our capital needs have been principally met through proceeds from the sale of equity and debt securities. We expect capital expenditures to be less than $100,000 during the next twelve months.

The following sets forth our primary sources of capital during the previous two years:

We entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has since been extended through October 31, ~~2019.~~2020. Pursuant to the terms of the arrangement, from time to time, we sell to the Factor a minimum of $150,000 of certain of our accounts receivable balances per quarter on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to us (the “Advance Amount”), with the remaining balance, less fees, ~~to be~~ forwarded to us once the Factor collects the full accounts receivable balance from the customer. In addition, from time to time, we receive over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored, and ~~are~~is determined by the number of days required for collection of the invoice. We expect to continue to use this factoring arrangement periodically to assist with our general working capital requirements due to contractual requirements.

On September 22, 2017, we issued to Wong Kwok Fong (Kelvin), a director, executive officer and principal stockholder of the Company, 427,778 shares of common stock and warrants to purchase 138,889 shares of common stock for an aggregate purchase price of $1,540,000, or $3.60 per share. The purchase consisted of a cash payment of $1,000,000 and the conversion of accrued dividends payable on the Company’s Series A-1 Convertible Preferred Stock of $540,000.
On August 24, 2018, we completed a public offering of units consisting of 1,380,000 shares of common stock and warrants to purchase 1,035,000 shares of common stock for an aggregate gross ~~proceeds~~proceed of $2,070,000, or $1.50 per unit. During the quarter ended March 31, 2020, 972,000 of the warrants were exercised resulting in proceeds of $1,428,000.

On ~~April 4,~~July 10, 2019, we issued a ~~$550,000~~$3,060,000 principal amount senior secured convertible ~~debenture~~note (the “Original Note”) to an institutional ~~investor which matures November 15, 2019~~investor. At closing, $2,550,000 was funded. The Note was secured by a lien on substantially all of our assets and isproperties and was convertible into shares of our common stock at a fixed conversion price of $1.50 per share. ~~The debenture may be redeemed at any time by payment~~Pursuant to amendments in the first and second quarter of ~~a premium~~2020, we amended the Original Note to increase the principal ~~balance starting at 5%~~amount to $3,789,000 as a result of interest and ~~increasing~~penalties, accelerated the maturity date to ~~20%~~June 13, 2020, and reduced the conversion price to $0.65 per share (the “Amended Note”). The ~~debenture was issued at a 7% original issue discount. On July 10, 2019 this debenture was redeemed and repaid in~~ full ~~in connection with~~balance of the ~~financing described below.~~Amended Note has been converted into common stock.

On ~~June 14, 2019,~~January 13, 2020, we issued a $157,000 principal amount convertible note to an institutional investor with a maturity date of June 13, 2020 which ~~matures November 14, 2019 and is~~was convertible into common stock at a conversion price of $1.50 per share. The note ~~may be redeemed~~was redeemable at any time by payment of a premium to the principal balance starting at 10% and increasing to 30%. ~~On July 10, 2019 this~~This note was ~~redeemed and repaid~~paid in full ~~in connection with the financing described below.~~on June 12, 2020 by payment of $211,984.

On ~~July 10, 2019,~~February 13, 2020, we issued a ~~$3,060,000~~$126,000 principal amount convertible note to an institutional investor with a maturity date of July 13, 2020 which was convertible into common stock at a conversion price of $1.15 per share. The note was redeemable at any time by payment of a premium to the principal balance starting at 10% and increasing to 30%. This note was paid in full on July 10, 2020 by payment of $170,442.
On April 20, 2020, we entered into a Paycheck Protection Program Term Note (the “SVB Note”) with Silicon Valley Bank (“SVB”) pursuant to the Paycheck Protection Program (the “Program”) of the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration. We received total proceeds of approximately $341,000 which will be used in accordance with the requirements of the CARES Act. We will apply to SVB for forgiveness of amounts due on the SVB Note to the extent they are used for eligible payroll costs, rent obligations, and covered utility payments incurred during the “covered period” following disbursement under the SVB Note. Until the six-month anniversary of the date of the SVB Note (the “Deferral Expiration Date”), neither principal nor interest is due and payable. On the Deferral Expiration Date, the outstanding principal of the SVB Note that is not forgiven will convert to an amortizing term loan at an interest rate of 1% per annum requiring equal monthly payments of principal and interest through November 20, 2022. We expect that the full amount of the SVB Note will be forgiven.
32
Table of Contents
On May 6, 2020, we issued a $2,415,000 principal amount senior secured convertible ~~note (the “Note”) to an institutional investor. At closing, $2,550,000 was funded.~~note. The principal amount ~~due of the Note is~~was due and payable ~~as follows: $918,000 is due 180 days~~in five equal monthly installments of $268,333 beginning seven months after the funding ~~$1,071,000 is due 270 days after funding, and~~date with the remaining balance is due 12twelve months after the date of funding. Following the completion of the underwritten offering consummated in July 2020 discussed below, all outstanding amounts relating this note were paid in full.
On June 29, 2020, we issued a $1,811,250 principal amount senior secured convertible note. The ~~Note is secured by a lien on substantially~~principal amount was due and payable in nine equal monthly installments of $201,250 beginning four months after the funding date. Following the completion of the underwritten offering consummated in July 2020 discussed below, all outstanding amounts relating this note were paid in full.
On July 23, 2020, we completed an underwritten public offering of ~~our assets and properties and is convertible into~~ shares of ~~our~~ common stock ~~at a fixed conversion price~~and warrants resulting in net proceeds of ~~$1.50 per share.~~ approximately $22.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. We used approximately $4.2 million of the net proceeds to repay all outstanding amounts due under our outstanding convertible promissory notes.

Liquidity outlook

At June 30, ~~2019,~~2020, our total cash and cash equivalents were approximately ~~$687,000,~~$887,000, as compared to approximately ~~$324,000~~$79,000 at December 31, ~~2018.~~2019.

As discussed above, we have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. We estimate that we currently require approximately ~~$537,000~~$680,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation. During the first half of ~~2019,~~2020, we generated approximately ~~$1,280,000~~$830,000 of revenue, which is below our average monthly requirements.
If we are unable to continue to generate sufficient revenue to meet our goals, we will need to obtain additional third-party financing to (i) conduct the sales, marketing and technical support necessary to execute our plan to substantially grow operations, increase revenue and serve a significant customer base; and (ii) provide working capital. We may, therefore, need to obtain additional financing through the issuance of debt or equity securities.

Due to several factors, including our history of losses and limited revenue, our independent auditors have included an explanatory paragraph in their opinion related to our annual financial statements as to the substantial doubt about our ability to continue as a going concern. In light of the completion of an underwritten public offering in July 2020, we expect that our current capital resources will be sufficient for us to (i) conduct the sales, marketing and technical support necessary to execute our plan to substantially grow operations, increase revenue and serve a significant customer base and (ii) satisfy our working capital needs for at least the next twelve months. Our long-term viability and growth will depend upon the successful commercialization of our technologies, and our ability to obtain adequate financing. To the extent that we require such additional financing, no assurance can be given that any form of additional financing will be available on terms acceptable to us, that adequate financing will be obtained to meet our needs, or that such financing would not be dilutive to existing stockholders. If available financing is insufficient or unavailable or we fail to continue to generate sufficient revenue, we may be required to reduce operating expenses, delay the expansion of operations, ~~be unable to pursue~~and pursuit of merger and acquisition candidates.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have, or ~~acquisition candidates, or~~are in the ~~extreme case, not continue as~~opinion of management reasonably likely to have, a ~~going concern.~~current or future effect on our financial condition or results of operations.

ITEM 4.  CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of June 30, ~~2019.~~2020. Based on the evaluation of our disclosure controls and procedures as of June 30, ~~2018,~~2020, our CEO and CFO concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

No change in our internal control over financial reporting occurred during the fiscal quarter ended June 30, ~~2019,~~2020, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

33
Table of Contents

PART II — OTHER INFORMATION
ITEM 1A. RISK FACTORS.
The recent outbreak of COVID-19 has and may continue to have a negative impact on our business, sales, results of operations and financial condition.
The global outbreak of COVID-19 has led to severe disruptions in general economic activities, particularly retail operations and travel, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. Individually and collectively, the consequences of the COVID-19 outbreak could have a material adverse effect on our business, sales, results of operations and financial condition. Although our employees have been accustomed to working remotely prior to the COVID-19 pandemic, the uncertainty has extended sales cycles, extended payment terms, impacted access to inventory overseas, and delayed the start of planned deployments, particularly in the continent of Africa which remains subject to shut-down and shelter at home orders.
Additionally, our liquidity could be negatively impacted if these conditions continue for a significant period of time and we may be required to pursue additional sources of financing to obtain working capital, maintain appropriate inventory levels, and meet our financial obligations. Currently capital and credit markets have been disrupted by the crisis and our ability to obtain any required financing is not guaranteed and largely dependent upon evolving market conditions and other factors. Depending on the continued impact of the crisis, further actions may be required. Our recent experience is that due to circumstances related to COVID-19, some of our customers have experienced delays in processing of orders for our products, which may delay certain anticipated revenues.
The extent to which the COVID-19 outbreak ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 outbreak has subsided, we may continue to experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.
We have taken measures to minimize the health risks of COVID-19 to our employees, as their safety and well-being are a top priority. Despite these efforts, there is a risk that one or more of our employees, including members of senior management, could contract COVID-19. Our U.S. employees are working remotely when possible, and we may experience reduced productivity due to the remote work environment. The extent to which COVID-19 impacts our business, sales and results of operations will depend on future developments, which are highly uncertain and cannot be predicted.
War, terrorism, other acts of violence or natural or manmade disasters such as a global pandemic may affect the markets in which the Company operates, the Company’s customers, the Company’s delivery of products and customer service, and could have a material adverse impact on our business, results of operations, or financial condition.
Our business may be adversely affected by instability, disruption or destruction in a geographic region in which we operate, regardless of cause, including war, terrorism, riot, civil insurrection or social unrest, and natural or manmade disasters, including famine, food, fire, earthquake, storm or pandemic events and spread of COVID-19, described above.
We may experience difficulties in integrating the operations, personnel and assets of PistolStar which we acquired in June 2020.
We recently acquired PistolStar. There can be no assurance that we will be able to manage PistolStar’s business or successfully integrate the business with our historic operations without substantial costs, delays or other operational or financial problems. In addition, we cannot assure you that we will be to maintain and grow the revenues and operating margins of the combined business, realize cost synergies with PistolStar’s products, services, and operations, or that we will be able to retain all of PistolStar’s existing customers and employees. If we are unable to successfully manage the new business, we will not be able to generate sufficient revenue to offset the acquisition costs that we have incurred which would have a material adverse effect on our financial positon and results of operations.
34
Table of Contents
We may pursue strategic acquisitions, including acquiring other identity access management companies, as part of our growth strategy and that may disrupt our growth.
We may pursue strategic acquisitions in the future. Risks in acquisition transactions include difficulties in the integration of acquired businesses into our operations and control environment, difficulties in assimilating and retaining employees and intermediaries, difficulties in retaining the existing clients of the acquired entities, assumed or unforeseen liabilities that arise in connection with the acquired businesses, the failure of counterparties to satisfy any obligations to indemnify us against liabilities arising from the acquired businesses, and unfavorable market conditions that could negatively impact our growth expectations for the acquired businesses. Fully integrating an acquired company or business into our operations may take a significant amount of time. We cannot assure you that we will be successful in overcoming these risks or any other problems encountered with acquisitions and other strategic transactions. These risks may prevent us from realizing the expected benefits from acquisitions and could result in the failure to realize the full economic value of a strategic transaction or the impairment of goodwill and/or intangible assets recognized at the time of an acquisition. These risks could be heightened if we complete a large acquisition or multiple acquisitions within a short period of time.  Additional risks may include:
difficulties in integrating operations, technologies, services and personnel;
the diversion of financial and management resources from existing operations;
the risk of entering new markets;
the potential loss of existing customers following an acquisition;
the potential loss of key employees and the associated risk of competitive efforts from such departed personnel; and
the inability to generate sufficient revenue to offset acquisition or investment costs.
As a result, if we fail to properly evaluate and execute any acquisitions or investments, our business and prospects may be seriously harmed.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~On April 4, 2019, we~~The Company issued a ~~$550,000 principal amount secured debenture due November 15, 2019 which is convertible into~~warrant to an investor for 125,000 shares of common stock exercisable at a ~~conversion~~ price of ~~$1.50~~$1.16 per share in consideration ~~of gross cash proceeds of $511,500. In connection with this financing, we issued 80,000 shares of common stock in payment of~~for a $120,000 commitment fee and agreed to issue 10,000 shares of common stock to the investor each month in payment of a monthly commitment fee of $15,000 until the earlier of November 1, 2019 or the repayment or conversion of the debenture. The debenture was redeemed and repaid in full on July 10, 2019.business referral. The foregoing securities were issued in a private placement transaction to one accredited investor pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, without general solicitation or advertising of any kind and without payment of placement agent or brokerage fees to any person.

~~On June 14, 2019, we issued a $157,000 note due November 13, 2019 which is convertible into shares~~
35
Table of common stock at a conversion price of $1.50 per share in consideration of gross cash proceeds of $157,000. In connection with this financing, we issued 200,000 shares of common stock in payment of a $30,000 commitment fee, 180,000 of which were returned to us since the note was redeemed in full on July 10, 2019 prior to the maturity date. The foregoing securities were issued in a private placement transaction to one accredited investor pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, without general solicitation or advertising of any kind and without payment of placement agent or brokerage fees to any person.
Contents

ITEM 6. EXHIBITS

Exhibit
No.

Description

~~10.1~~2.1 ~~Securities~~Stock Purchase Agreement ~~dated July 10, 2019~~ by and ~~between~~among the ~~Registrant~~Company, Thomas J. Hoey, and ~~Lind Global Macro Fund, LP.,~~PistolStar, Inc. dated June 6, 2020 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K, filed with the SEC on July 7, 2020).

~~10.2~~
10.1
Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 issued by the Company to Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.3 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)

10.2
~~Security Agreement dated July 10, 2019~~Amendment to Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 by and between the ~~Registrant~~Company and Lind Global Macro Fund, LP dated April 12, 2020. (incorporated by reference to Exhibit 10.4 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
10.3
Securities Purchase Agreement dated May 6, 2020 by and between the Company and Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.5 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
10.4
$2,415,000 Senior Secured Convertible Promissory Note dated May 6, 2020. (incorporated by reference to Exhibit 10.6 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
10.5
Amended and Restated Security Agreement dated May 6, 2020 by and between the Company and Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.8 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)

~~10.3~~10.6 ~~Collateral Sharing Agreement~~$1,811,250 Senior Secured Convertible Promissory Note dated June 29, 2020. (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the SEC on July ~~10, 2019 by and among the Registrant, Lind Global Macro Fund, LP and Versant Funding LLC.~~1, 2020)

~~10.4~~10.7 ~~$3,060,00 Senior Secured Convertible Promissory Note~~Common Stock Purchase Warrant dated May 6, 2020. (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the SEC on July ~~10, 2019.~~1, 2020)

~~10.5~~10.8 ~~Common Stock~~Amendment No. 2 to Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 by and between the Company and Lind Global Macro Fund, LP dated May 13, 2020. (incorporated by reference to Exhibit 10.9 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
10.9 Second Amended and Restated Security Agreement dated June 29, 2020 by and between the Company and Lind Global Macro Fund, LP (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed with the SEC on July 1, 2020)
10.10 $500,000 Promissory note, dated June 30, 2020 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on July 7, 2020).
10.11 Securities Purchase ~~Warrant~~Agreement dated June 29, 2020 by and between the Company and Lind Global Macro Fund, LP (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on July ~~10, 2019.~~1, 2020)

31.1

Certificate of CEO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended

31.2

Certificate of CFO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended

32.1

Certificate of CEO of Registrant required under 18 U.S.C. Section 1350

32.2

Certificate of CFO of Registrant required under 18 U.S.C. Section 1350

101.INS

XBRL Instance

101.SCH

XBRL Taxonomy Extension Schema

101.CAL

XBRL Taxonomy Extension Calculation

101.DEF

XBRL Taxonomy Extension Definition

101.LAB

XBRL Taxonomy Extension Labels

101.PRE

XBRL Taxonomy Extension Presentation

36
Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



BIO-Key International, Inc.



Dated: August 14, ~~2019~~2020

/s/ Michael W. DePasquale


Michael W. DePasquale


Chief Executive Officer


(Principal Executive Officer)



Dated: August 14, ~~2019~~2020

/s/ Cecilia C. Welch


Cecilia C. Welch


Chief Financial Officer

(Principal Financial Officer)

31
37

	Series A-1 Preferred Stock				Series B-1 Preferred Stock				Common Stock				Additional Paid-in			Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Total
Balance as of December 31, 2018		-	$	-		-	$	-		13,977,868	$	1,398	$	85,599,140		$	(75,134,316	)	$	10,466,222
Issuance of common stock for directors’ fees		-		-		-		-		13,820		1		16,505			-			16,506
Share-based compensation		-		-		-		-		-		-		509,528			-			509,528
Net loss		-		-		-		-		-		-		-			(1,803,508	)		(1,803,508	)
Balance as of March 31, 2019		-	$	-		-	$	-		13,991,688	$	1,399	$	86,125,173		$	(76,937,824	)	$	9,188,748
Issuance of common stock for directors’ fees		-		-		-		-		4,235		-		5,505			-			5,505
Issuance of common stock for commitment fees		-		-		-		-		300,000		30		449,970			-			450,000
Commitment fee adjustment		-		-		-		-		-		-		(270,000	)		-			(270,000	)
Share-based compensation		-		-		-		-		-		-		125,549			-			125,549
Net loss		-		-		-		-		-		-		-			(1,425,743	)		(1,425,743	)
Balance as of June 30, 2019		-	$	-		-	$	-		14,295,923	$	1,429	$	86,436,197		$	(78,363,567	)	$	8,074,059

	As reported		Adoption of ASC			Balance
	December 31, 2018		842 - increase (decrease)			January 1, 2019
Operating lease right-of-assets	$	-	$	602,937		$	602,937
Prepaid expenses and other	$	150,811	$	(12,595	)	$	138,216
Total assets	$	11,692,332	$	590,342		$	12,282,674
Operating lease liabilities, current portion	$	-	$	135,519		$	135,519
Operating lease liabilities, net of current portion	$	-	$	454,823		$	454,823
Total liabilities	$	1,226,110	$	590,342		$	1,816,452
Total liabilities and stockholders’ equity	$	11,692,332	$	590,342		$	12,282,674

Purchase consideration:
Total cash paid, net of acquired cash	$	2,000,000
4% Promissory note		500,000
Total purchase price consideration	$	2,500,000

Fair value of assets acquired and liabilities assumed:
Cash and cash equivalents	$	100,747
Accounts receivable		184,792
Prepaid expenses and other current assets		9,485
Fixed assets		36,467
Intangible assets		2,005,000
Goodwill		417,171
Total assets acquired		2,753,662

Accrued expenses and other current liabilities		494
Deferred revenue		253,168
Total fair value of assets acquired and liabilities assumed	$	2,500,000

	Amount		Estimated useful life (in years)
Developed technology	$	1,153,000		3
Customer relationships		852,000		5
Total identifiable intangible assets	$	2,005,000

	3 Months ended June 30,			6 Months ended June 30,
	2020			2020

Revenue	$	725,779		$	1,652,678
Net loss		(1,580,349	)		(5,045,889	)
Basic and diluted net loss per share	$	(0.08	)	$	(0.28	)
Weighted average number of ordinary shares used in computing basic and diluted loss per share		20,864,866			18,030,939

	As reported			Prior methodology			As reported			Prior methodology
	3 months ended			3 months ended			6 months ended			6 months ended
	June 30, 2019			June 30, 2019			June 30, 2019			June 30, 2019
Amortization of software license rights	$	281,076		$	749,826		$	562,150		$	1,499,650
Total operating expenses	$	1,359,888		$	1,828,638		$	3,111,039		$	4,048,539
Operating loss	$	(1,310,931	)	$	(1,779,681	)	$	(3,114,509	)	$	(4,052,009	)
Net loss	$	(1,425,743	)	$	(1,894,493	)	$	(3,229,251	)	$	(4,166,751	)
Basic & diluted loss per share	$	(0.10	)	$	(0.13	)	$	(0.23	)	$	(0.29	)

Principal amount	$	707,000
Less unamortized debt discount		(24,533	)
Less unamortized debt issuance costs		(140,800	)
Notes payable, net of unamortized debt discount and debt issuance costs	$	541,667

	Series A-1			Accrued Dividends

Balance – January 1, 2017		90,000		$	270,000
Accrual of dividends – Q1 2017		-			135,000
Accrual of dividends – Q2 2017		-			135,000
Accrual of dividends – Q3 2017		-			135,000
Conversion into common stock – September 2017		-			(540,000	)
Conversion into common stock – October 2017		(27,404	)		-
Accrual of dividends – Q4 2017					101,658
Balance – December 31, 2017		62,596		$	236,658
Accrual of dividends – Q1 2018		-			93,894
Conversion into common stock – April 2018		(39,088	)		(330,552	)
Accrual of dividends – Q2 2018 (until final conversion)		-			25,463
Conversion into common stock – May 2018		(23,508	)		(25,463	)
Balance – December 31, 2018		-		$	-

	Series B-1			Accrued Dividends

Balance – January 1, 2017		105,000		$	131,250
Accrual of dividends – Q1 2017		-			65,625
Accrual of dividends – Q2 2017		-			65,625
Accrual of dividends – Q3 2017		-			65,625
Accrual of dividends – Q4 2017		-			65,625
Balance – December 31, 2017		105,000			393,750
Conversion into common stock – March 2018		(60,420	)		(417,084	)
Accrual of dividends – Q1 2018		-			62,268
Accrual of dividends – Q2 2018 (until final conversion)		-			16,408
Conversion into common stock – May 2018		(44,580	)		(55,342	)
Balance – December 31, 2018		-		$	-

	Three months ended
	June 30,
	2020			2019			$ Change			% Change

Other income (expense)	$	(200,896	)	$	(114,812	)	$	(86,084	)		75	%

	Six months ended
	June 30,
	2020			2019			$ Change			% Change

Other income (expense)	$	(2,251,112	)	$	(114,742	)	$	(2,136,370	)		1,862	%

	●	Net positive cash flows related to adjustments for non-cash expenses for depreciation, amortization, share-based and warrant based compensation, debt discounts and issuance costs, loss on extinguishment of debt, the amortization of a beneficial conversion feature, non-cash interest expense, and issuance of common stock to our non-employee directors, of approximately ~~$1,405,000, and a decrease in accounts receivable, combined with increases in accounts payable, accruals and deferred revenue of approximately $1,674,000.~~$3,492,000.

	●	Net negative cash flows related to ~~reductions due from factor~~accounts payable, accruals and operating lease liabilities of approximately ~~$148,000.~~$582,000.

Exhibit No.		Description

~~10.1~~2.1		~~Securities~~Stock Purchase Agreement ~~dated July 10, 2019~~ by and ~~between~~among the ~~Registrant~~Company, Thomas J. Hoey, and ~~Lind Global Macro Fund, LP.,~~PistolStar, Inc. dated June 6, 2020 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K, filed with the SEC on July 7, 2020).

~~10.2~~ 10.1		Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 issued by the Company to Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.3 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)

10.2		~~Security Agreement dated July 10, 2019~~Amendment to Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 by and between the ~~Registrant~~Company and Lind Global Macro Fund, LP dated April 12, 2020. (incorporated by reference to Exhibit 10.4 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)

10.3		Securities Purchase Agreement dated May 6, 2020 by and between the Company and Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.5 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)

10.4		$2,415,000 Senior Secured Convertible Promissory Note dated May 6, 2020. (incorporated by reference to Exhibit 10.6 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)

10.5		Amended and Restated Security Agreement dated May 6, 2020 by and between the Company and Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.8 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)

~~10.3~~10.6		~~Collateral Sharing Agreement~~$1,811,250 Senior Secured Convertible Promissory Note dated June 29, 2020. (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the SEC on July ~~10, 2019 by and among the Registrant, Lind Global Macro Fund, LP and Versant Funding LLC.~~1, 2020)

~~10.4~~10.7		~~$3,060,00 Senior Secured Convertible Promissory Note~~Common Stock Purchase Warrant dated May 6, 2020. (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the SEC on July ~~10, 2019.~~1, 2020)

~~10.5~~10.8		~~Common Stock~~Amendment No. 2 to Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 by and between the Company and Lind Global Macro Fund, LP dated May 13, 2020. (incorporated by reference to Exhibit 10.9 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)

10.9		Second Amended and Restated Security Agreement dated June 29, 2020 by and between the Company and Lind Global Macro Fund, LP (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed with the SEC on July 1, 2020)

10.10		$500,000 Promissory note, dated June 30, 2020 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on July 7, 2020).

10.11		Securities Purchase ~~Warrant~~Agreement dated June 29, 2020 by and between the Company and Lind Global Macro Fund, LP (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on July ~~10, 2019.~~1, 2020)

31.1		Certificate of CEO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended

31.2		Certificate of CFO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended

32.1		Certificate of CEO of Registrant required under 18 U.S.C. Section 1350

32.2		Certificate of CFO of Registrant required under 18 U.S.C. Section 1350

101.INS		XBRL Instance

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation

101.DEF		XBRL Taxonomy Extension Definition

101.LAB		XBRL Taxonomy Extension Labels

101.PRE		XBRL Taxonomy Extension Presentation

		BIO-Key International, Inc.

Dated: August 14, ~~2019~~2020		/s/ Michael W. DePasquale
		Michael W. DePasquale
		Chief Executive Officer
		(Principal Executive Officer)

Dated: August 14, ~~2019~~2020		/s/ Cecilia C. Welch
		Cecilia C. Welch
		Chief Financial Officer
		(Principal Financial Officer)